

A. ORIGINE DU RAPPORT

A1		Name of contracting Party: France
A3k		Web page https://sante.gouv.fr/
1		Period of reporting:
	1	Start date January 2021
	1	End date December 2022

B1. CONSOMMATION DE TABAC

B1		Prevalence of tobacco use
B11		Smoking prevalence in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered, e.g. 15 years old and over, 18-64 years; see B112)
1_SQ001		Current smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 34.7%
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day] 11.4
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 29.2%
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day] 9.7
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 31.9%
	3_SQ002	TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day] 10.6
1_SQ001		Daily smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 27.8%
	1_SQ002	MALE [Average number of the most-consumed smoking tobacco product used per day] 13.5
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 23.0%
	2_SQ002	FEMALE [Average number of the most-consumed smoking tobacco product used per day] 11.8
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 25.3%
	3_SQ002	TOTAL (males and females) [Average number of the most-consumed smoking tobacco product used per day] 12.7
1_SQ001		Occasional smokers

	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 6.9
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 6.3
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 6.6
1_SQ001		Former smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 34.2
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 29.5
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 31.8
1_SQ001		Never smokers
	1_SQ001	MALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 31.1
	2_SQ001	FEMALE [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 41.3
	3_SQ001	TOTAL (males and females) [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 36.3
B111		Please indicate the smoking tobacco products included in calculating prevalence for question B11: cigarettes manufacturées, tabac à rouler, pipe, cigares, cigarillos, chicha
1_SQ001		Please indicate the age range to which the data used to answer question B11 refer:
	1_SQ001	Age range [From] 18
	1_SQ002	Age range [To] 75
B113A		Please indicate the year of the data used to answer question B11: 2020
B113B		Please indicate the source of the data used to answer question B11: Baromètre santé 2021 (Santé publique France)
SQ001		Please provide the definitions of “current smoker”, “daily smoker”, “occasional smoker”, “former smoker” and “never smoker” used in this report.

	SQ001	Current smoker qui déclare fumer au moins de temps en temps des cigarettes manufacturées, du tabac à rouler, ou d'autres produits du tabac (pipe, cigares, cigarillos, chicha)
	SQ002	Daily smoker qui déclare fumer tous les jours ou déclarant un nombre de cigarettes fumées par jour
	SQ003	Occasional smoker qui déclare fumer moins d'un produit du tabac à fumer par jour
	SQ004	Former smoker qui déclare ne pas fumer actuellement, mais avoir déjà fumé de manière quotidienne ou occasionnelle
	SQ005	Never smoker qui déclare n'avoir jamais fumé ou juste pour essayer
B115		Please provide a brief explanation of the trend in smoking prevalence in the adult population in the past two years or since submission of your last report. Après une période de baisse de la prévalence du tabagisme entre 2016 et 2019, une stabilité du tabagisme quotidien est observée. Un impact de la crise liée à la Covid-19 ne peut être exclu sur l'interruption de la baisse de la prévalence du tabagisme en France.
B12a_B12x1		Smoking prevalence in the adult population (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current smokers1 [Range - start age] 18
	B12a_B12x3	MALES - current smokers1 [Range - end age] 24
	B12a_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 43.5
	B12b_B12x1	MALES - current smokers1 [Range - start age] 25
	B12b_B12x3	MALES - current smokers1 [Range - end age] 34
	B12b_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 48.4
	B12c_B12x1	MALES - current smokers1 [Range - start age] 35
	B12c_B12x3	MALES - current smokers1 [Range - end age] 44
	B12c_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 43.3
	B12d_B12x1	MALES - current smokers1 [Range - start age]

		45
	B12d_B12x3	MALES - current smokers1 [Range - end age] 54
	B12d_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 35.3
	B12e_B12x1	MALES - current smokers1 [Range - start age] 55
	B12e_B12x3	MALES - current smokers1 [Range - end age] 64
	B12e_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 27.1
	B12ee_B12x1	MALES - current smokers1 [Range - start age] 65
	B12ee_B12x3	MALES - current smokers1 [Range - end age] 75
	B12ee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 14.2
	B12eee_B12x1	MALES - current smokers1 [Range - start age]
	B12eee_B12x3	MALES - current smokers1 [Range - end age]
	B12eee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eeee_B12x1	MALES - current smokers1 [Range - start age]
	B12eeee_B12x3	MALES - current smokers1 [Range - end age]
	B12eeee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12eeee_B12x1	MALES - current smokers1 [Range - start age]
	B12eeee_B12x3	MALES - current smokers1 [Range - end age]
	B12eeee_B12x2	MALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12f_B12x1	FEMALES - current smokers1 [Range - start age] 18
	B12f_B12x3	FEMALES - current smokers1 [Range - end age] 24
	B12f_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 41.8

	B12g_B12x1	FEMALES - current smokers1 [Range - start age] 25
	B12g_B12x3	FEMALES - current smokers1 [Range - end age] 34
	B12g_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 36.3
	B12h_B12x1	FEMALES - current smokers1 [Range - start age] 35
	B12h_B12x3	FEMALES - current smokers1 [Range - end age] 44
	B12h_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 33.4
	B12i_B12x1	FEMALES - current smokers1 [Range - start age] 45
	B12i_B12x3	FEMALES - current smokers1 [Range - end age] 54
	B12i_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 32.8
	B12j_B12x1	FEMALES - current smokers1 [Range - start age] 55
	B12j_B12x3	FEMALES - current smokers1 [Range - end age] 64
	B12j_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 25.1
	B12jj_B12x1	FEMALES - current smokers1 [Range - start age] 65
	B12jj_B12x3	FEMALES - current smokers1 [Range - end age] 75
	B12jj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 11.9
	B12jjj_B12x1	FEMALES - current smokers1 [Range - start age]
	B12jjj_B12x3	FEMALES - current smokers1 [Range - end age]
	B12jjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]

	B12jjj_B12x1	FEMALES - current smokers1 [Range - start age]
	B12jjj_B12x3	FEMALES - current smokers1 [Range - end age]
	B12jjj_B12x2	FEMALES - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12k_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 18
	B12k_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 24
	B12k_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 42.6
	B12l_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 25
	B12l_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 34
	B12l_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 42.2
	B12m_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 35
	B12m_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 44
	B12m_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 38.2
	B12n_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 45
	B12n_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 54
	B12n_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 34.0
	B12o_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 55
	B12o_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 64

	B12o_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 26.1
	B12oo_B12x1	TOTAL (males and females) - current smokers1 [Range - start age] 65
	B12oo_B12x3	TOTAL (males and females) - current smokers1 [Range - end age] 75
	B12oo_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)] 13.0
	B12ooo_B12x1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12ooo_B12x3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12ooo_B12x2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	B12oooo_B12x 1	TOTAL (males and females) - current smokers1 [Range - start age]
	B12oooo_B12x 3	TOTAL (males and females) - current smokers1 [Range - end age]
	B12oooo_B12x 2	TOTAL (males and females) - current smokers1 [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
B121		Please indicate the smoking tobacco products included in calculating prevalence for question B12: Cigarettes manufacturées, tabac à rouler, pipe, cigares, cigarillos
B122A		Please indicate the year of the data used to answer question B12: 2020
B122B		Please indicate the source of the data used to answer question B12: Baromètre santé 2021 (Santé publique France)
B123		Please provide a brief explanation of the trend in current smoking prevalence by age group in the past two years or since submission of your last report, if data are available. Les évolutions diffèrent selon les classes d'âge et le sexe. Parmi les hommes de 18-24 ans, la prévalence du tabagisme quotidien diminue entre 2020 et 2021 alors qu'elle est stable chez les femmes dans cette tranche d'âge (27,9% en 2021). Aucune évolution significative n'est observée dans les autres tranches d'âge. Parmi les femmes, une tendance à la hausse est néanmoins observée entre 35 et 54 ans.
B13		Prevalence of smokeless tobacco use in the adult population (all) (Please provide prevalence data for total adult population, and identify the age considered in B132, e.g. 15 years old and over, 18–64 years; see B132)
1_B13x1		Males

	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
1_B13x1		Females
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
1_B13x1		TOTAL (males and females)
	1_B13x1	Current users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	2_B13x1	Daily users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	3_B13x1	Occasional users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	4_B13x1	Former users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

	5_B13x1	Never users [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B131		Please indicate the smokeless tobacco products included in calculating prevalence for question B13:
1_SQ001		Please indicate the age range to which the data used to answer question B13 refer:
	1_SQ001	Age range [From]
	1_SQ002	Age range [To]
B133A		Please indicate the year of the data used to answer question B13:
B133B		Please indicate the source of the data used to answer question B13:
SQ001		Please provide the definitions of “current user”, “daily user”, “occasional user”, “former user” and “never user” (of smokeless tobacco products) used in this report in the space below.
	SQ001	Current user
	SQ002	Daily user
	SQ003	Occasional user
	SQ004	Former user
	SQ005	Never user
B135		Please provide a brief explanation of the trend in smokeless tobacco use in the adult population in the past two years or since submission of your last report.
B12a_B12x1		Prevalence of smokeless tobacco use in the adult population (current users) by age group (by age groups)(If data are available, please provide prevalence data by age group, and identify the age group considered, preferably by 10-year categories, e.g. 25-34, 35-44 years)
	B12a_B12x1	MALES - current users2 [Age group (adults)]
	B12a_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]

	B12b_B12x1	MALES - current users2 [Age group (adults)]
	B12b_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12c_B12x1	MALES - current users2 [Age group (adults)]
	B12c_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12d_B12x1	MALES - current users2 [Age group (adults)]
	B12d_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12e_B12x1	MALES - current users2 [Age group (adults)]
	B12e_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12ee_B12x1	MALES - current users2 [Age group (adults)]
	B12ee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12eee_B12x1	MALES - current users2 [Age group (adults)]
	B12eee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12eeee_B12x1	MALES - current users2 [Age group (adults)]
	B12eeee_B12x2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12eeee_B12x1 1	MALES - current users2 [Age group (adults)]
	B12eeee_B12x2 2	MALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12f_B12x1	FEMALES - current users2 [Age group (adults)]
	B12f_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12g_B12x1	FEMALES - current users2 [Age group (adults)]

	B12g_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12h_B12x1	FEMALES - current users2 [Age group (adults)]
	B12h_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12i_B12x1	FEMALES - current users2 [Age group (adults)]
	B12i_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12j_B12x1	FEMALES - current users2 [Age group (adults)]
	B12j_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jjj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12jjjj_B12x1	FEMALES - current users2 [Age group (adults)]
	B12jjjj_B12x2	FEMALES - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12k_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12k_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12l_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12l_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless

		tobacco products in prevalence data]]
	B12m_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12m_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12n_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12n_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12o_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12o_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12oo_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12oo_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12ooo_B12x1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12ooo_B12x2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
	B12oooo_B12x 1	TOTAL (males and females) - current users2 [Age group (adults)]
	B12oooo_B12x 2	TOTAL (males and females) - current users2 [Prevalence (%) (please include all smokeless tobacco products in prevalence data)]
B141		Please indicate the smokeless tobacco products included in the answer to question B14:
B142A		Please indicate the year of the data used to answer question B14:
B142B		Please indicate the source of the data used to answer question B14:
B143		Please provide a brief explanation of the trend in current use of smokeless tobacco by adult age groups in the past two years or since submission of your last report.
B15a_B15x1		Tobacco use by ethnic group(s) (please include all smoking or smokeless tobacco products

		in prevalence data)
	B15a_B15x1	Current users 3 [Ethnic group(s)]
	B15a_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15a_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15a_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15b_B15x1	Current users 3 [Ethnic group(s)]
	B15b_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15b_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15b_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15c_B15x1	Current users 3 [Ethnic group(s)]
	B15c_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15c_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15c_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15d_B15x1	Current users 3 [Ethnic group(s)]
	B15d_B15x2	Current users 3 [MALES - Prevalence (%)]
	B15d_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15d_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
	B15e_B15x1	Current users 3 [Ethnic group(s)]
	B15e_B15x2	Current users 3 [MALES - Prevalence (%)]

	B15e_B15x3	Current users 3 [FEMALES - Prevalence (%)]
	B15e_B15x4	Current users 3 [TOTAL (males and females) - Prevalence (%)]
B151		Please indicate the tobacco products included in the answer to question B15:
1_SQ001		Please indicate the age range to which the data used to answer question B15 refer:
	1_SQ001	Age range [From]
	1_SQ002	Age range [To]
B153A		Please indicate the year of the data used to answer question B15:
B153B		Please indicate the source of the data used to answer question B15:
B16a_B16x1		Tobacco use by young persons (please include all smoking or smokeless tobacco products in prevalence data)
	B16a_B16x1	BOYS - Current users 4 [Age range] 17 ans
	B16a_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 17.0
	B16a_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16a_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)] 13.1
	B16b_B16x1	BOYS - Current users 4 [Age range]
	B16b_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16b_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16b_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16c_B16x1	BOYS - Current users 4 [Age range]
	B16c_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]

	B16c_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16c_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16d_B16x1	BOYS - Current users 4 [Age range]
	B16d_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16d_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16d_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16e_B16x1	BOYS - Current users 4 [Age range]
	B16e_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16e_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16e_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16ee_B16x1	BOYS - Current users 4 [Age range]
	B16ee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16ee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16ee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16eee_B16x1	BOYS - Current users 4 [Age range]
	B16eee_B16x2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16eee_B16x3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16eee_B16x4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16eeee_B16x 1	BOYS - Current users 4 [Age range]

B16eeee_B16x 2	BOYS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16eeee_B16x 3	BOYS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16eeee_B16x 4	BOYS - Current users 4 [WATER PIPE - Prevalence (%)]
B16f_B16x1	GIRLS - Current users 4 [Age range] 17 ans
B16f_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 14.2
B16f_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16f_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)] 7.9
B16g_B16x1	GIRLS - Current users 4 [Age range]
B16g_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16g_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16g_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16h_B16x1	GIRLS - Current users 4 [Age range]
B16h_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16h_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16h_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
B16i_B16x1	GIRLS - Current users 4 [Age range]
B16i_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
B16i_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
B16i_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]

	B16j_B16x1	GIRLS - Current users 4 [Age range]
	B16j_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16j_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16j_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16jj_B16x1	GIRLS - Current users 4 [Age range]
	B16jj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16jj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16jj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16jjj_B16x1	GIRLS - Current users 4 [Age range]
	B16jjj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16jjj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16jjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16jjjj_B16x1	GIRLS - Current users 4 [Age range]
	B16jjjj_B16x2	GIRLS - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16jjjj_B16x3	GIRLS - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16jjjj_B16x4	GIRLS - Current users 4 [WATER PIPE - Prevalence (%)]
	B16k_B16x1	TOTAL (boys and girls) - Current users 4 [Age range] 17 ans
	B16k_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)] 15.6
	B16k_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]

	B16k_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)] 10.6
	B16l_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16l_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16l_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16l_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16m_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16m_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16m_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16m_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16n_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16n_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16n_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16n_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16o_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16o_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16o_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16o_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16oo_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16oo_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]

	B16oo_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16oo_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16ooo_B16x1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16ooo_B16x2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16ooo_B16x3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16ooo_B16x4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
	B16oooo_B16x 1	TOTAL (boys and girls) - Current users 4 [Age range]
	B16oooo_B16x 2	TOTAL (boys and girls) - Current users 4 [SMOKING TOBACCO - Prevalence (%)]
	B16oooo_B16x 3	TOTAL (boys and girls) - Current users 4 [SMOKELESS TOBACCO - Prevalence (%)]
	B16oooo_B16x 4	TOTAL (boys and girls) - Current users 4 [WATER PIPE - Prevalence (%)]
B161		Please indicate the tobacco products included in calculating prevalence for question B16: Cigarettes manufacturées, cigares et cigarillos
B162A		Please indicate the year of the data used to answer question B16: 2021
B162B		Please indicate the source of the data used to answer question B16: Enquête ESCAPAD 2022
B163		Please provide the definition of “current smoking/tobacco use” used to answer question B16 in the space below. a) « Tabac à fumer » il s'agit des fumeurs quotidiens, part des adolescents ayant déclaré avoir fumé au moins une cigarette par jours au cours des 30 derniers jours b) « Pipe à eau » : part des adolescents ayant déclaré au moins un usage au cours des 30 derniers jours c) « Inhalateurs électroniques » part des usagers quotidiens (i.e. au moins un usage par jours au cours des 30 derniers jours) remarque : l'enquête ne permet pas de distinguer avec ou sans nicotine.
B164		Please provide a brief explanation of the trend in tobacco use by young persons in the past two years or since submission of your last report. Parmi les adolescents âgés de 17 ans, la prévalence tabagique quotidienne a baissé de 38% entre 2017 et 2022
SQ001_SQ001		Male
	SQ001_SQ001	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Prevalence (%) (please include all smoking tobacco products in prevalence data)]

	SQ001_SQ002	Prevalence (%) (please include all smoking tobacco products in prevalence data) [Average number of the most-consumed smoking tobacco product used per day]
	SQ002_SQ001	Average number of the most-consumed smoking tobacco product used per day [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ002_SQ002	Average number of the most-consumed smoking tobacco product used per day [Average number of the most-consumed smoking tobacco product used per day]
	SQ003_SQ001	Occasional smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ003_SQ002	Occasional smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ004_SQ001	Former smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ004_SQ002	Former smokers [Average number of the most-consumed smoking tobacco product used per day]
	SQ005_SQ001	Never smokers [Prevalence (%) (please include all smoking tobacco products in prevalence data)]
	SQ005_SQ002	Never smokers [Average number of the most-consumed smoking tobacco product used per day]
1_1		Use of novel and emerging tobacco and nicotine products
	1_1	Age range [Age range] 18-75
	1_2	Age range [Heated tobacco products (HTPs) - Prevalence (%)]
	1_3	Age range [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 7.5
	1_4	Age range [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	1_5	Age range [Other products - Prevalence (%)]
	2_1	Heated tobacco products (HTPs) - Prevalence (%) [Age range] 18-75
	2_2	Heated tobacco products (HTPs) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]

	2_3	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 6.0
	2_4	Heated tobacco products (HTPs) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	2_5	Heated tobacco products (HTPs) - Prevalence (%) [Other products - Prevalence (%)]
	3_1	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Age range] 18-75
	3_2	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)] 1%
	3_3	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 6.7
	3_4	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	3_5	Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%) [Other products - Prevalence (%)]
	4_1	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Age range] 17 ans
	4_2	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	4_3	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 6.0
	4_4	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%)]
	4_5	Electronic Non-Nicotine Delivery Systems (ENNDS) - Prevalence (%) [Other products - Prevalence (%)]
	5_1	Other products - Prevalence (%) [Age range] 17 ans
	5_2	Other products - Prevalence (%) [Heated tobacco products (HTPs) - Prevalence (%)]
	5_3	Other products - Prevalence (%) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)]

		6.3
	5_4	Other products - Prevalence (%) [Electronic Non-Nicotine Delivery Systems (ENNDs) - Prevalence (%)]
	5_5	Other products - Prevalence (%) [Other products - Prevalence (%)]
	6_1	YOUNG PERSONS - Total (boys and girls) [Age range] 17 ans
	6_2	YOUNG PERSONS - Total (boys and girls) [Heated tobacco products (HTPs) - Prevalence (%)]
	6_3	YOUNG PERSONS - Total (boys and girls) [Electronic Nicotine Delivery Systems (ENDS) - Prevalence (%)] 6.2
	6_4	YOUNG PERSONS - Total (boys and girls) [Electronic Non-Nicotine Delivery Systems (ENNDs) - Prevalence (%)]
	6_5	YOUNG PERSONS - Total (boys and girls) [Other products - Prevalence (%)]
B171		Please indicate the year and source of the data used to answer question B17. 2021
B172		Please provide a brief explanation of the trends – in adults and in young persons – in the use of novel and emerging tobacco and nicotine products in the past two years or since submission of your last report. EN 2020, 37,4 % des 18-75 ans ont expérimenté la cigarette électronique, proportion en hausse par rapport à 2019. L'usage en 2020 était déclaré par 5,4 % d'entre eux, tandis que l'usage quotidien concerne 4,3 % des adultes ; ce pourcentage es en hausse en 2021.

B2-B9. INDICATEURS SANITAIRES, SOCIAUX ET ÉCONOMIQUES CONNEXES

B2		Exposure to tobacco smoke
B21		Do you have any data on exposure to tobacco smoke in your population? Yes
B22		Please provide details in the space below (e.g. exposure by gender, at home, in the workplace, on public transport). les dernières données datent de 2018 (lieux d'habitation) et 2017 (lieux de travail)
B23A		Please indicate the year of the data used to answer question B21: 2017
B23B		Please indicate the source of the data used to answer question B21: Quatremère G, Pasquereau A, Guignard R, Andler R, Nguyen-Thanh V et les groupes Baromètre de Santé publique France 2017 et 2018. Exposition à la fumée de tabac sur le lieu de travail et au domicile entre 2014 et 2018 : résultats du Baromètre de Santé publique France, 2020. 13 p Pasquereau A, Guignard R, Andler R, Richard JB, Arwidson P, Beck F, et al. L'exposition à la fumée de tabac dans les lieux à usage collectif et les lieux de convivialité en France en 2014. Bull Epidemiol Hebd. 2016;(15):253-63. http://invs.santepubliquefrance.fr/beh/2016/15/2016_15_1.html
B3		Tobacco-related mortality
B31		Do you have information on tobacco-related mortality in your population? Yes
B32		What is the estimated total number of deaths attributable to tobacco use in your population? En 2015, il a été estimé que plus de 75 000 décès étaient attribuables au tabagisme, ce qui correspond à environ 13% des décès survenus en France métropolitaine.
B33		If available, please provide any additional information on mortality attributable to tobacco use (e.g. lung cancer, cardiovascular diseases) in your jurisdiction. En 2015, 75 320 décès ont été estimés attribuables au tabagisme. Ces estimations se répartissaient entre 55 420 décès attribuables chez les hommes et 19 900 décès attribuables chez les femmes, ce qui représentait 19,3% et 6,9% respectivement de l'ensemble des décès. La cause de décès attribuables au tabagisme était un cancer pour 61,7% des personnes (hommes : 36 577, 66% ; femmes : 9 868, 49%), une maladie cardio-vasculaire pour 22,1% (hommes : 11 135, 20% ; femmes : 5 526, 28%) et une pathologie respiratoire pour 16,2% (hommes : 7 675, 14%, femmes : 4 492, 23%). Les évolutions entre 2000 et 2015 montrent une tendance décroissante des nombres de décès attribuables au tabagisme chez les hommes (-11% en 15 ans). À l'inverse, le nombre de décès attribuables chez les femmes a été multiplié par 2,5 sur la même période en passant de 8 027 décès en 2000 à 19 900 décès attribuables au tabagisme en 2015. Entre 2000 et 2015, la proportion de décès attribuables au tabagisme a ainsi augmenté en moyenne de 5,4% par an chez les femmes contre une diminution de 1,1% chez les hommes. L'étude complète et détaillée se trouve dans l'article cité en source.
B34A		Please indicate the year of the data used to answer question B32 and 33: 2015
B34B		Please indicate the source of the data used to answer questions B32 and B33: Bonaldi C, Boussac M, Nguyen-Thanh V. Estimation du nombre de décès attribuables au tabagisme, en France de 2000 à 2015. Bull Epidemiol Hebd. 2019;(15):278-84. http://beh.santepubliquefrance.fr/beh/2019/15/2019_14_2.html
B4		Tobacco-related costs

B41		<p>Do you have information on the economic burden of tobacco use in your population, e.g. the overall cost of tobacco use imposed on your society?</p> <p>Yes</p>
B42		<p>Please provide details (e.g. direct (health care-related) and indirect costs and, if possible, the method used to estimate these costs).</p> <p>Les dernières données disponibles datent d'un étude de 2015 (données analysés de 2010)</p>
B43A		<p>Please indicate the year of the data used to answer question B42:</p> <p>2010</p>
B43B		<p>Please indicate the source of the data used to answer question B42:</p> <p>KOPP Pierre Le coût social des drogues en France , OFDT 2015 https://www.ofdt.fr/BDD/publications/docs/eisxpkv9.pdf</p>
B5		<p>Supply of tobacco and tobacco products (with reference to Articles 6.2(b), 20.4(c), and 15.5)</p>
B51a_B51x1		<p>Licit supply of tobacco products</p>
	B51a_B51x1	<p>Smoking tobacco products [Product]</p> <p>Cigarettes</p>
	B51a_B51x2	<p>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</p> <p>unités</p>
	B51a_B51x3	<p>Smoking tobacco products [Domestic production]</p>
	B51a_B51x4	<p>Smoking tobacco products [Retail sales]</p>
	B51a_B51x5	<p>Smoking tobacco products [Exports]</p>
	B51a_B51x6	<p>Smoking tobacco products [Imports]</p>
	B51b_B51x1	<p>Smoking tobacco products [Product]</p> <p>tabac à rouler</p>
	B51b_B51x2	<p>Smoking tobacco products [Unit (e.g. pieces, tonnes)]</p> <p>grammes</p>
	B51b_B51x3	<p>Smoking tobacco products [Domestic production]</p>
	B51b_B51x4	<p>Smoking tobacco products [Retail sales]</p>
	B51b_B51x5	<p>Smoking tobacco products [Exports]</p>
	B51b_B51x6	<p>Smoking tobacco products [Imports]</p>
	B51c_B51x1	<p>Smoking tobacco products [Product]</p>

		autres tabacs à fumer
	B51c_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)] grammes
	B51c_B51x3	Smoking tobacco products [Domestic production]
	B51c_B51x4	Smoking tobacco products [Retail sales]
	B51c_B51x5	Smoking tobacco products [Exports]
	B51c_B51x6	Smoking tobacco products [Imports]
	B51cc_B51x1	Smoking tobacco products [Product] cigares et cigarillos
	B51cc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)] unités
	B51cc_B51x3	Smoking tobacco products [Domestic production]
	B51cc_B51x4	Smoking tobacco products [Retail sales]
	B51cc_B51x5	Smoking tobacco products [Exports]
	B51cc_B51x6	Smoking tobacco products [Imports]
	B51ccc_B51x1	Smoking tobacco products [Product]
	B51ccc_B51x2	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B51ccc_B51x3	Smoking tobacco products [Domestic production]
	B51ccc_B51x4	Smoking tobacco products [Retail sales]
	B51ccc_B51x5	Smoking tobacco products [Exports]
	B51ccc_B51x6	Smoking tobacco products [Imports]
	B51cccc_B51x 1	Smoking tobacco products [Product]
	B51cccc_B51x	Smoking tobacco products [Unit (e.g. pieces, tonnes)]

	2	
	B51cccc_B51x3	Smoking tobacco products [Domestic production]
	B51cccc_B51x4	Smoking tobacco products [Retail sales]
	B51cccc_B51x5	Smoking tobacco products [Exports]
	B51cccc_B51x6	Smoking tobacco products [Imports]
	B51d_B51x1	Smokeless tobacco products [Product] tabac à priser
	B51d_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)] grammes
	B51d_B51x3	Smokeless tobacco products [Domestic production]
	B51d_B51x4	Smokeless tobacco products [Retail sales]
	B51d_B51x5	Smokeless tobacco products [Exports]
	B51d_B51x6	Smokeless tobacco products [Imports]
	B51e_B51x1	Smokeless tobacco products [Product] tabac à mâcher
	B51e_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)] grammes
	B51e_B51x3	Smokeless tobacco products [Domestic production]
	B51e_B51x4	Smokeless tobacco products [Retail sales]
	B51e_B51x5	Smokeless tobacco products [Exports]
	B51e_B51x6	Smokeless tobacco products [Imports]
	B51f_B51x1	Smokeless tobacco products [Product]
	B51f_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51f_B51x3	Smokeless tobacco products [Domestic production]

	B51f_B51x4	Smokeless tobacco products [Retail sales]
	B51f_B51x5	Smokeless tobacco products [Exports]
	B51f_B51x6	Smokeless tobacco products [Imports]
	B51ff_B51x1	Smokeless tobacco products [Product]
	B51ff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51ff_B51x3	Smokeless tobacco products [Domestic production]
	B51ff_B51x4	Smokeless tobacco products [Retail sales]
	B51ff_B51x5	Smokeless tobacco products [Exports]
	B51ff_B51x6	Smokeless tobacco products [Imports]
	B51fff_B51x1	Smokeless tobacco products [Product]
	B51fff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51fff_B51x3	Smokeless tobacco products [Domestic production]
	B51fff_B51x4	Smokeless tobacco products [Retail sales]
	B51fff_B51x5	Smokeless tobacco products [Exports]
	B51fff_B51x6	Smokeless tobacco products [Imports]
	B51ffff_B51x1	Smokeless tobacco products [Product]
	B51ffff_B51x2	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B51ffff_B51x3	Smokeless tobacco products [Domestic production]
	B51ffff_B51x4	Smokeless tobacco products [Retail sales]

	B51fff_B51x5	Smokeless tobacco products [Exports]
	B51fff_B51x6	Smokeless tobacco products [Imports]
	B51g_B51x1	Other tobacco products [Product]
	B51g_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51g_B51x3	Other tobacco products [Domestic production]
	B51g_B51x4	Other tobacco products [Retail sales]
	B51g_B51x5	Other tobacco products [Exports]
	B51g_B51x6	Other tobacco products [Imports]
	B51h_B51x1	Other tobacco products [Product]
	B51h_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51h_B51x3	Other tobacco products [Domestic production]
	B51h_B51x4	Other tobacco products [Retail sales]
	B51h_B51x5	Other tobacco products [Exports]
	B51h_B51x6	Other tobacco products [Imports]
	B51i_B51x1	Other tobacco products [Product]
	B51i_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51i_B51x3	Other tobacco products [Domestic production]
	B51i_B51x4	Other tobacco products [Retail sales]
	B51i_B51x5	Other tobacco products [Exports]

	B51i_B51x6	Other tobacco products [Imports]
	B51ii_B51x1	Other tobacco products [Product]
	B51ii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51ii_B51x3	Other tobacco products [Domestic production]
	B51ii_B51x4	Other tobacco products [Retail sales]
	B51ii_B51x5	Other tobacco products [Exports]
	B51ii_B51x6	Other tobacco products [Imports]
	B51iii_B51x1	Other tobacco products [Product]
	B51iii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51iii_B51x3	Other tobacco products [Domestic production]
	B51iii_B51x4	Other tobacco products [Retail sales]
	B51iii_B51x5	Other tobacco products [Exports]
	B51iii_B51x6	Other tobacco products [Imports]
	B51iiii_B51x1	Other tobacco products [Product]
	B51iiii_B51x2	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B51iiii_B51x3	Other tobacco products [Domestic production]
	B51iiii_B51x4	Other tobacco products [Retail sales]
	B51iiii_B51x5	Other tobacco products [Exports]
	B51iiii_B51x6	Other tobacco products [Imports]

	B51j_B51x1	Tobacco leaves [Product]
	B51j_B51x2	Tobacco leaves [Unit (e.g. pieces, tonnes)]
	B51j_B51x3	Tobacco leaves [Domestic production]
	B51j_B51x4	Tobacco leaves [Retail sales]
	B51j_B51x5	Tobacco leaves [Exports]
	B51j_B51x6	Tobacco leaves [Imports]
B52		Please provide information on the volumes of duty-free sales (e.g. product, unit, quantity), if available.
B53A		Please indicate the year of the data used to answer question B51 and 52: 2021
B53B		Please indicate the source of the data used to answer questions B51 and B52: Direction générale des douanes et droits indirects DGDDI et Logista, principal fournisseur agréé
B6		Seizures of illicit tobacco products (with reference to Article 15.5)
B61a_B61x1		Seizures of illicit tobacco
	B61a_B61x1	Smoking tobacco products [Year]
	B61a_B61x2	Smoking tobacco products [Product]
	B61a_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61a_B61x4	Smoking tobacco products [Quantity seized]
	B61b_B61x1	Smoking tobacco products [Year]
	B61b_B61x2	Smoking tobacco products [Product]
	B61b_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]

	B61b_B61x4	Smoking tobacco products [Quantity seized]
	B61c_B61x1	Smoking tobacco products [Year]
	B61c_B61x2	Smoking tobacco products [Product]
	B61c_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61c_B61x4	Smoking tobacco products [Quantity seized]
	B61cc_B61x1	Smoking tobacco products [Year]
	B61cc_B61x2	Smoking tobacco products [Product]
	B61cc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61cc_B61x4	Smoking tobacco products [Quantity seized]
	B61ccc_B61x1	Smoking tobacco products [Year]
	B61ccc_B61x2	Smoking tobacco products [Product]
	B61ccc_B61x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61ccc_B61x4	Smoking tobacco products [Quantity seized]
	B61cccc_B61x 1	Smoking tobacco products [Year]
	B61cccc_B61x 2	Smoking tobacco products [Product]
	B61cccc_B61x 3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
	B61cccc_B61x 4	Smoking tobacco products [Quantity seized]
	B61ccccc_B61 x1	Smoking tobacco products [Year]
	B61ccccc_B61 x2	Smoking tobacco products [Product]

B61cccc_B61 x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61cccc_B61 x4	Smoking tobacco products [Quantity seized]
B61cccccc_B6 1x1	Smoking tobacco products [Year]
B61cccccc_B6 1x2	Smoking tobacco products [Product]
B61cccccc_B6 1x3	Smoking tobacco products [Unit (e.g. pieces, tonnes)]
B61cccccc_B6 1x4	Smoking tobacco products [Quantity seized]
B61d_B61x1	Smokeless tobacco products [Year]
B61d_B61x2	Smokeless tobacco products [Product]
B61d_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61d_B61x4	Smokeless tobacco products [Quantity seized]
B61e_B61x1	Smokeless tobacco products [Year]
B61e_B61x2	Smokeless tobacco products [Product]
B61e_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61e_B61x4	Smokeless tobacco products [Quantity seized]
B61f_B61x1	Smokeless tobacco products [Year]
B61f_B61x2	Smokeless tobacco products [Product]
B61f_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
B61f_B61x4	Smokeless tobacco products [Quantity seized]
B61ff_B61x1	Smokeless tobacco products [Year]

	B61ff_B61x2	Smokeless tobacco products [Product]
	B61ff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ff_B61x4	Smokeless tobacco products [Quantity seized]
	B61fff_B61x1	Smokeless tobacco products [Year]
	B61fff_B61x2	Smokeless tobacco products [Product]
	B61fff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61fff_B61x4	Smokeless tobacco products [Quantity seized]
	B61ffff_B61x1	Smokeless tobacco products [Year]
	B61ffff_B61x2	Smokeless tobacco products [Product]
	B61ffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ffff_B61x4	Smokeless tobacco products [Quantity seized]
	B61fffff_B61x1	Smokeless tobacco products [Year]
	B61fffff_B61x2	Smokeless tobacco products [Product]
	B61fffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61fffff_B61x4	Smokeless tobacco products [Quantity seized]
	B61ffffff_B61x1	Smokeless tobacco products [Year]
	B61ffffff_B61x2	Smokeless tobacco products [Product]
	B61ffffff_B61x3	Smokeless tobacco products [Unit (e.g. pieces, tonnes)]
	B61ffffff_B61x4	Smokeless tobacco products [Quantity seized]

	B61g_B61x1	Other tobacco products [Year]
	B61g_B61x2	Other tobacco products [Product]
	B61g_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61g_B61x4	Other tobacco products [Quantity seized]
	B61h_B61x1	Other tobacco products [Year]
	B61h_B61x2	Other tobacco products [Product]
	B61h_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61h_B61x4	Other tobacco products [Quantity seized]
	B61i_B61x1	Other tobacco products [Year]
	B61i_B61x2	Other tobacco products [Product]
	B61i_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61i_B61x4	Other tobacco products [Quantity seized]
	B61ii_B61x1	Other tobacco products [Year]
	B61ii_B61x2	Other tobacco products [Product]
	B61ii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61ii_B61x4	Other tobacco products [Quantity seized]
	B61iii_B61x1	Other tobacco products [Year]
	B61iii_B61x2	Other tobacco products [Product]
	B61iii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]

	B61iii_B61x4	Other tobacco products [Quantity seized]
	B61iii_B61x1	Other tobacco products [Year]
	B61iii_B61x2	Other tobacco products [Product]
	B61iii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iii_B61x4	Other tobacco products [Quantity seized]
	B61iiii_B61x1	Other tobacco products [Year]
	B61iiii_B61x2	Other tobacco products [Product]
	B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiii_B61x4	Other tobacco products [Quantity seized]
	B61iiii_B61x1	Other tobacco products [Year]
	B61iiii_B61x2	Other tobacco products [Product]
	B61iiii_B61x3	Other tobacco products [Unit (e.g. pieces, tonnes)]
	B61iiii_B61x4	Other tobacco products [Quantity seized]
B62		Do you have any information on the percentage of illicit tobacco products on the national tobacco market? Yes
B63		What percentage of the national tobacco market do illicit tobacco products constitute? (%)
B64		What is the trend over the past two years or since submission of your last report in the percentage of illicit tobacco products in relation to the national tobacco market?
B65		Please provide any further information on illicit tobacco products.
B66		Please indicate the source of the data used to answer questions in section B6:
B7		Tobacco-growing

B71		<p>Is there any tobacco-growing in your jurisdiction?</p> <p>No</p>
B72		<p>Please provide information on the number of workers involved in tobacco-growing. If available, please provide this figure broken down by gender.</p>
B73		<p>Please provide, if available, the share of the value of tobacco leaf production in the national gross domestic product.</p>
B74A		<p>Please indicate the year of the data used to answer questions in section B7:</p>
B74B		<p>Please indicate the source of the data used to answer questions in section B7:</p>
B8		<p>Taxation of tobacco products (with reference to Articles 6.2(a) and 6.3)</p>
B81		<p>What proportion of the retail price of the most popular price category of tobacco product consists of taxes (e.g. sum of excise, sales and import duties (if applicable) and value added tax/goods and services tax (VAT/GST))?</p>
SQ001		<p>How are the excise taxes levied (what types of taxes are levied)?</p>
	SQ001	<p>Specific tax only</p> <p>No</p>
	SQ002	<p>Ad valorem tax only</p> <p>No</p>
	SQ003	<p>Combination of specific and ad valorem taxes</p> <p>Yes</p>
	SQ004	<p>More complex structure (please explain below)</p> <p>Yes</p>
B82a		<p>If a more complex structure of taxes (please explain):</p> <p>Le système de taxes comporte aussi un minimum de perception le cas échéant (article 575 du code général des impôts).</p>
B83a_B83x1		<p>If available, please provide details on the rates of taxation for tobacco products at all levels of Government and be as specific as possible (specify the type of tax, e.g. VAT, sales, import duties)</p>
	B83a_B83x1	<p>Smoking tobacco products [Product]</p> <p>tous</p>
	B83a_B83x2	<p>Smoking tobacco products [Type of tax]</p> <p>TVA</p>
	B83a_B83x3	<p>Smoking tobacco products [Rate or amount]</p>

	B83a_B83x4	Smoking tobacco products [Base of tax5] prix de vente au détail
	B83b_B83x1	Smoking tobacco products [Product] cigarettes
	B83b_B83x2	Smoking tobacco products [Type of tax] Accise spécifique
	B83b_B83x3	Smoking tobacco products [Rate or amount] 55
	B83b_B83x4	Smoking tobacco products [Base of tax5] pour mille unités ou mille grammes
	B83c_B83x1	Smoking tobacco products [Product] cigarettes
	B83c_B83x2	Smoking tobacco products [Type of tax] Accise proportionnelle
	B83c_B83x3	Smoking tobacco products [Rate or amount] 63.5
	B83c_B83x4	Smoking tobacco products [Base of tax5] Prix de vente au détail
	B83cc_B83x1	Smoking tobacco products [Product] Cigares et cigarillos
	B83cc_B83x2	Smoking tobacco products [Type of tax] Accise spécifique
	B83cc_B83x3	Smoking tobacco products [Rate or amount] 36.3
	B83cc_B83x4	Smoking tobacco products [Base of tax5] pour mille unités ou mille grammes
	B83ccc_B83x1	Smoking tobacco products [Product] Cigares et cigarillos
	B83ccc_B83x2	Smoking tobacco products [Type of tax] Accise proportionnelle
	B83ccc_B83x3	Smoking tobacco products [Rate or amount] 48.6
	B83ccc_B83x4	Smoking tobacco products [Base of tax5] Prix de vente au détail
	B83cccc_B83x 1	Smoking tobacco products [Product] Tabac fine coupe destiné à rouler les cigarettes
	B83cccc_B83x 2	Smoking tobacco products [Type of tax] Accise spécifique

B83cccc_B83x 3	Smoking tobacco products [Rate or amount] 49.1
B83cccc_B83x 4	Smoking tobacco products [Base of tax5] les 1000 grammes
B83cccc_B83 x1	Smoking tobacco products [Product] Tabac fine coupe destiné à rouler les cigarettes
B83cccc_B83 x2	Smoking tobacco products [Type of tax] Accise proportionnelle
B83cccc_B83 x3	Smoking tobacco products [Rate or amount] 83.30
B83cccc_B83 x4	Smoking tobacco products [Base of tax5] Prix de vente au détail
B83cccc_B8 3x1	Smoking tobacco products [Product]
B83cccc_B8 3x2	Smoking tobacco products [Type of tax]
B83cccc_B8 3x3	Smoking tobacco products [Rate or amount]
B83cccc_B8 3x4	Smoking tobacco products [Base of tax5]
B83d_B83x1	Smokeless tobacco products [Product] tabac à priser
B83d_B83x2	Smokeless tobacco products [Type of tax] Accise proportionnelle
B83d_B83x3	Smokeless tobacco products [Rate or amount] 58.1
B83d_B83x4	Smokeless tobacco products [Base of tax5] Prix de vente au détail
B83e_B83x1	Smokeless tobacco products [Product] tabac à mâcher
B83e_B83x2	Smokeless tobacco products [Type of tax] Accise proportionnelle
B83e_B83x3	Smokeless tobacco products [Rate or amount] 40.7
B83e_B83x4	Smokeless tobacco products [Base of tax5] Prix de vente au détail
B83f_B83x1	Smokeless tobacco products [Product]

	B83f_B83x2	Smokeless tobacco products [Type of tax]
	B83f_B83x3	Smokeless tobacco products [Rate or amount]
	B83f_B83x4	Smokeless tobacco products [Base of tax5]
	B83ff_B83x1	Smokeless tobacco products [Product]
	B83ff_B83x2	Smokeless tobacco products [Type of tax]
	B83ff_B83x3	Smokeless tobacco products [Rate or amount]
	B83ff_B83x4	Smokeless tobacco products [Base of tax5]
	B83fff_B83x1	Smokeless tobacco products [Product]
	B83fff_B83x2	Smokeless tobacco products [Type of tax]
	B83fff_B83x3	Smokeless tobacco products [Rate or amount]
	B83fff_B83x4	Smokeless tobacco products [Base of tax5]
	B83ffff_B83x1	Smokeless tobacco products [Product]
	B83ffff_B83x2	Smokeless tobacco products [Type of tax]
	B83ffff_B83x3	Smokeless tobacco products [Rate or amount]
	B83ffff_B83x4	Smokeless tobacco products [Base of tax5]
	B83fffff_B83x1	Smokeless tobacco products [Product]
	B83fffff_B83x2	Smokeless tobacco products [Type of tax]
	B83fffff_B83x3	Smokeless tobacco products [Rate or amount]
	B83fffff_B83x4	Smokeless tobacco products [Base of tax5]

	B83fffff_B83x1	Smokeless tobacco products [Product]
	B83fffff_B83x2	Smokeless tobacco products [Type of tax]
	B83fffff_B83x3	Smokeless tobacco products [Rate or amount]
	B83fffff_B83x4	Smokeless tobacco products [Base of tax5]
	B83g_B83x1	Other tobacco products [Product] Autres tabacs à fumer
	B83g_B83x2	Other tobacco products [Type of tax] Accise proportionnelle
	B83g_B83x3	Other tobacco products [Rate or amount] 50.7%
	B83g_B83x4	Other tobacco products [Base of tax5] Prix de vente au détail
	B83h_B83x1	Other tobacco products [Product] Autres tabacs à fumer
	B83h_B83x2	Other tobacco products [Type of tax] Accise spécifique
	B83h_B83x3	Other tobacco products [Rate or amount] 29.10€
	B83h_B83x4	Other tobacco products [Base of tax5] les 1000 grammes
	B83i_B83x1	Other tobacco products [Product]
	B83i_B83x2	Other tobacco products [Type of tax]
	B83i_B83x3	Other tobacco products [Rate or amount]
	B83i_B83x4	Other tobacco products [Base of tax5]
	B83ii_B83x1	Other tobacco products [Product]
	B83ii_B83x2	Other tobacco products [Type of tax]
	B83ii_B83x3	Other tobacco products [Rate or amount]

	B83ii_B83x4	Other tobacco products [Base of tax5]
	B83iii_B83x1	Other tobacco products [Product]
	B83iii_B83x2	Other tobacco products [Type of tax]
	B83iii_B83x3	Other tobacco products [Rate or amount]
	B83iii_B83x4	Other tobacco products [Base of tax5]
	B83iiii_B83x1	Other tobacco products [Product]
	B83iiii_B83x2	Other tobacco products [Type of tax]
	B83iiii_B83x3	Other tobacco products [Rate or amount]
	B83iiii_B83x4	Other tobacco products [Base of tax5]
	B83iiiii_B83x1	Other tobacco products [Product]
	B83iiiii_B83x2	Other tobacco products [Type of tax]
	B83iiiii_B83x3	Other tobacco products [Rate or amount]
	B83iiiii_B83x4	Other tobacco products [Base of tax5]
	B83iiiiii_B83x1	Other tobacco products [Product]
	B83iiiiii_B83x2	Other tobacco products [Type of tax]
	B83iiiiii_B83x3	Other tobacco products [Rate or amount]
	B83iiiiii_B83x4	Other tobacco products [Base of tax5]
B84		Please briefly describe the trends in taxation for tobacco products in the past two years or since submission of your last report in your jurisdiction.
B85		Do you earmark any percentage of your taxation income for funding any national plan or strategy on tobacco control in your jurisdiction?

		Yes
B86		<p>Please provide details in the space below.</p> <p>Le Fonds de lutte contre le tabac était financé en 2018 et 2019 par un prélèvement sur le chiffre d'affaires des fournisseurs de tabac, destiné au financement d'actions locales, nationales et internationales de lutte contre le tabac. Ce prélèvement a été arrêté par la loi de finances pour 2020, au profit d'une valorisation des taux d'accises des différentes catégories fiscales à partir du 1er mars 2020.</p>
B87A		<p>Please indicate the year of the data used to answer questions B81 to B86:</p> <p>2001</p>
B87B		<p>Please indicate the source of the data used to answer questions B81 to B86:</p> <p>Données fiscales et prix de vente au détail au 1er mars 2021. DGDDI</p>
B9		Price of tobacco products (with reference to Articles 6.2(a))
1_SQ001		Domestic Please provide the retail prices of the three most widely sold brands of domestic tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	1_SQ002	Smoking tobacco products [Number of units or amount per package]
	1_SQ003	Smoking tobacco products [Retail price]
	1_SQ004	Smoking tobacco products [Currency]
	2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	2_SQ002	Smoking tobacco products [Number of units or amount per package]
	2_SQ003	Smoking tobacco products [Retail price]
	2_SQ004	Smoking tobacco products [Currency]
	3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	3_SQ002	Smoking tobacco products [Number of units or amount per package]
	3_SQ003	Smoking tobacco products [Retail price]
	3_SQ004	Smoking tobacco products [Currency]
	7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]

	7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	7_SQ003	Smokeless tobacco products [Retail price]
	7_SQ004	Smokeless tobacco products [Currency]
	8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	8_SQ002	Smokeless tobacco products [Number of units or amount per package]
	8_SQ003	Smokeless tobacco products [Retail price]
	8_SQ004	Smokeless tobacco products [Currency]
	9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	9_SQ002	Smokeless tobacco products [Number of units or amount per package]
	9_SQ003	Smokeless tobacco products [Retail price]
	9_SQ004	Smokeless tobacco products [Currency]
	13_SQ001	Other tobacco products [Name of the most widely sold brand]
	13_SQ002	Other tobacco products [Number of units or amount per package]
	13_SQ003	Other tobacco products [Retail price]
	13_SQ004	Other tobacco products [Currency]
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]
	14_SQ004	Other tobacco products [Currency]

	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
1_SQ001		Imported Please provide the retail prices of the three most widely sold brands of imported tobacco products at the most widely used point of sale in your capital city.
	1_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	1_SQ002	Smoking tobacco products [Number of units or amount per package]
	1_SQ003	Smoking tobacco products [Retail price]
	1_SQ004	Smoking tobacco products [Currency]
	2_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	2_SQ002	Smoking tobacco products [Number of units or amount per package]
	2_SQ003	Smoking tobacco products [Retail price]
	2_SQ004	Smoking tobacco products [Currency]
	3_SQ001	Smoking tobacco products [Name of the most widely sold brand]
	3_SQ002	Smoking tobacco products [Number of units or amount per package]
	3_SQ003	Smoking tobacco products [Retail price]
	3_SQ004	Smoking tobacco products [Currency]
	7_SQ001	Smokeless tobacco products [Name of the most widely sold brand]

	7_SQ002	Smokeless tobacco products [Number of units or amount per package]
	7_SQ003	Smokeless tobacco products [Retail price]
	7_SQ004	Smokeless tobacco products [Currency]
	8_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	8_SQ002	Smokeless tobacco products [Number of units or amount per package]
	8_SQ003	Smokeless tobacco products [Retail price]
	8_SQ004	Smokeless tobacco products [Currency]
	9_SQ001	Smokeless tobacco products [Name of the most widely sold brand]
	9_SQ002	Smokeless tobacco products [Number of units or amount per package]
	9_SQ003	Smokeless tobacco products [Retail price]
	9_SQ004	Smokeless tobacco products [Currency]
	13_SQ001	Other tobacco products [Name of the most widely sold brand]
	13_SQ002	Other tobacco products [Number of units or amount per package]
	13_SQ003	Other tobacco products [Retail price]
	13_SQ004	Other tobacco products [Currency]
	14_SQ001	Other tobacco products [Name of the most widely sold brand]
	14_SQ002	Other tobacco products [Number of units or amount per package]
	14_SQ003	Other tobacco products [Retail price]
	14_SQ004	Other tobacco products [Currency]

	15_SQ001	Other tobacco products [Name of the most widely sold brand]
	15_SQ002	Other tobacco products [Number of units or amount per package]
	15_SQ003	Other tobacco products [Retail price]
	15_SQ004	Other tobacco products [Currency]
B92A		Please indicate the year of the data used to answer question B91: 2021
B92B		Please indicate the source of the data used to answer question B91:
B93		Please briefly describe the trend in the prices of tobacco products in the past two years or since submission of your last report in your jurisdiction.

C1. OBLIGATIONS GÉNÉRALES

C1		With reference to Article 5
C111		Have you developed and implemented comprehensive multisectoral national tobacco control strategies, plans and programmes in accordance with the Convention? Yes
C112		Have you partially developed and implemented tobacco control strategies by including tobacco control in national health, public health or health promotion strategies, plans and programmes? N/A
C113		Is any aspect of tobacco control that is referred to in the Convention included in any national strategy, plan or programme? N/A
C114a		Have you established or reinforced and financed:
	C114a	a focal point for tobacco control? Yes
	C114b	a tobacco control unit? Yes
	C114c	a national coordinating mechanism for tobacco control? Yes
C115		Please provide details (e.g. the nature of the national coordinating mechanism, the institution to which the focal point for tobacco control or the tobacco control unit belongs). Au sein du Ministère de la santé et de la prévention, la direction générale de la santé est composée de quatre sous-directions chargées des politiques de santé, de veille et de sécurité sanitaire, dont la Sous-direction de la santé des populations et de la prévention des maladies chroniques (SP). SP élabore et assure le pilotage stratégique des politiques publiques en matière de santé des populations et de prévention des maladies chroniques, somatiques transmissibles et non transmissibles, des maladies mentales, ainsi que des maladies à prévention vaccinale. Elle élabore ou participe à l'élaboration des textes législatifs et réglementaires dans ces domaines. Elle participe à l'élaboration et au suivi des actions et des textes européens et internationaux dans ces domaines. Elle assure ses missions en partenariat avec les régimes d'assurance maladie, les professionnels de santé et les associations. Elle s'appuie sur les diagnostics des agences régionales de santé (ARS) auxquelles elle apporte son appui pour la mise en œuvre des stratégies, plans et programmes. La sous-direction de la santé des populations et de la prévention des maladies chroniques comprend 5 unités : Le bureau de la santé des populations et de la politique vaccinale ; Le bureau des infections par le VIH, les IST, les hépatites et la tuberculose ; le bureau de la prévention des addictions (SP3) ; le bureau de la santé mentale et le bureau des maladies chroniques non transmissibles. Le bureau SP3 élabore et anime le volet sanitaire de la politique de lutte contre les pratiques addictives (substances psychoactives licites et illicites et addictions sans substance). Il participe aux instances européennes et internationales sur cette thématique. Il agit en coordination avec les autres directions du ministère, la mission interministérielle de lutte contre les drogues et conduites addictives (MILDECA), les autres ministères concernés (intérieur, agriculture, budget, justice...) et instances concernées (ANSP, OFDT, ANESM, Anses...) Ce bureau est chargé des trois principaux axes du dossier tabac : Évolution et suivi de la réglementation nationale et européenne ; Prévention et prise en charge du tabagisme (mise en œuvre du PNRT); Suivi pour la France de la convention cadre de lutte antitabac (CCLAT) de l'OMS ; Par ailleurs, le Plan national de lutte contre le tabac(PNLT) prévoit deux instances de gouvernance : - Le comité du Pilotage du PNLT, organe stratégique conformé par les directions ministérielles et les agences directement concernées par la mise en œuvre du PNLT ; -Et le comité de coordination, instance de consultation plus vaste à la que participent toutes les instances publiques concernées et les parties prenantes de la société civile (associations de patients, associations de lutte contre le tabac)
C116		Please provide a brief description of the progress made in implementing Article 5.1 and 5.2 (General obligations) in the past two years or since submission of your last report.

C117		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C12		Protection of public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C121		protecting public health policies with respect to tobacco control from commercial and other vested interests of the tobacco industry? Yes
C122		ensuring that the public has access, in accordance with Article 12(c), to a wide range of information on tobacco industry activities relevant to the objectives of the Convention, such as in a public repository? Yes
C123		If you answered “Yes” to any of the questions under C121 or C122, please provide details in the space below (specifically, please refer, if relevant, to whether your government or any of its departments 1) have raised awareness on tobacco industry tactics and the need to prevent interference by the tobacco industry with decision making; 2) have avoided entering into any partnerships or voluntary agreements with the tobacco industry; 3) have established any measures to limit interaction of public officials with the tobacco industry, including in the form of a code of conduct; 4) have not granted any incentives, privileges, benefits or preferential tax exemptions to the tobacco industry to establish or run their business; etc.). 1) votre gouvernement ou l'un de ses ministères a été sensibilisé aux tactiques de l'industrie du tabac et à la nécessité d'empêcher l'ingérence de l'industrie du tabac dans la prise de décisions. Non. 2) a évité de conclure des partenariats ou des accords volontaires avec l'industrie du tabac. Oui 3) a mis en place des mesures pour limiter l'interaction des agents publics avec l'industrie du tabac, y compris sous la forme d'un code de conduite; Non 4) n'a pas accordé d'incitations, de privilèges, d'avantages ou d'exonérations fiscales à l'industrie du tabac pour installer ou gérer leur(s) entreprise; etc.). Oui. Il n'existe pas de code de conduite à l'attention de la fonction publique ou des agents publics concernant spécifiquement les relations avec l'industrie du tabac. Par contre, l'article 26 de la loi du 26 janvier 2016 de modernisation de notre système de santé a posé un principe de transparence des relations d'influence de l'industrie du tabac. En application de cet article a été pris le décret n°2017-279 du 2 mars 2017 relatif à la transparence des dépenses liées aux activités d'influence ou de représentation d'intérêts des fabricants, importateurs, distributeurs de produits du tabac et de leurs représentants. Ces relations sont déclarées par les fabricants de tabac chaque année au ministère de la santé. Les déclarations sont consultables sur le site du ministère de la santé et restent accessibles pendant cinq ans, à compter de leur mise en ligne : http://solidarites-sante.gouv.fr/prevention-ensante/addictions/article/transparence-des-relations-d-influence-de-l-industrie-du-tabac En parallèle, toutes les actions d'influence sont déclarées également à l'Haute autorité pour la transparence de la vie publique, en application de la loi n° 2013-907 du 11 octobre 2013 relative à la transparence de la vie publique
C124		Please provide a brief description of the progress made in implementing Article 5.3 in the past two years or since submission of your last report. Pour la sixième année consécutive, les fabricants, les importateurs et les distributeurs de produits du tabac ainsi que les entreprises, organisations professionnelles ou les associations les représentants ont déclaré auprès du ministère de la santé et de la prévention l'ensemble des dépenses liées à des activités d'influence ou de représentation d'intérêts réalisés au titre de l'année 2021. 30 entreprises ont déclaré n'avoir réalisé aucune dépense relative à des activités d'influence ou de représentation d'intérêts. 8 entreprises ont déclaré des dépenses de cette nature pour un montant total de 717 945,50 euros. Parmi ces 8 entreprises déclarantes : – 6 ont déclaré des dépenses de rémunération de personnels employés en totalité ou en partie pour exercer des activités d'influence et de représentation d'intérêts au titre de l'année 2021. Ces dépenses s'élèvent à 102 950,50 euros. – 6 ont déclaré des dépenses d'achats de prestations auprès des sociétés de conseil en activités d'influence ou de représentation d'intérêts au titre de l'année 2021 s'élevant à 614 884 euros. – 1 a déclaré des avantages en nature ou en espèces à un député pour un montant de 111 euros.
C125		Have you utilized the “Guidelines for implementation of Article 5.3 of the WHO FCTC” when

		developing or implementing policies in this area? Yes
C126		Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/index.php/862235?token={TOKEN}&lang=en
C127		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

C2. MESURES RELATIVES À LA RÉDUCTION DE LA DEMANDE DE TABAC

C2		With reference to Articles 6–14
C21		Price and tax measures to reduce the demand for tobacco Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C211		tax policies and, where appropriate, price policies on tobacco products so as to contribute to the health objectives aimed at reducing tobacco consumption? Yes
C212		prohibiting or restricting, as appropriate, sales to international travellers of tax- and duty-free tobacco products? No
C213		prohibiting or restricting, as appropriate, imports by international travellers of tax- and duty-free tobacco products? Yes
C214		Please provide a brief description of the progress made in implementing Article 6 (Price and tax measures to reduce the demand for tobacco) in the past two years or since submission of your last report. La trajectoire fiscale 2018-2020 sur les produits du tabac ayant pris fin, il convient toutefois de veiller à ce que les prix conservent leur effet dissuasif et en outre de tirer les conséquences de cette hausse pour l'ensemble des produits du tabac, indexés sur l'inflation hors tabac de l'année N-2, dans la limite de 1,8 %. Ainsi, le prix des produits du tabac étant essentiellement constitué de taxes, il est spontanément très peu sensible à l'inflation et, dans un contexte de hausse généralisée des prix des biens et services de consommation courante, ainsi que des salaires, son prix relatif tend à diminuer. Il apparaît donc nécessaire d'indexer plus efficacement qu'aujourd'hui la fiscalité du tabac, aux évolutions de l'inflation. En effet, les tarifs ne sont revalorisés qu'avec un décalage de 2 ans et dans la limite de 1,8% alors que l'inflation est aujourd'hui nettement supérieure. Ainsi, les tarifs pour 2023 sont revalorisés à hauteur de l'inflation hors tabac constatée pour 2021 et prévue pour 2022 (ce niveau sera déterminé dans le rapport économique, social et financier annexé à loi de finances 2023. A compter du 1er janvier 2024, ils seront revalorisés sur la base de la prévision d'inflation hors tabac pour l'année précédente, éventuellement régularisée l'année suivante en cas d'écart, sans mécanisme de plafonnement. Le minimum de perception sera quant à lui revalorisé selon le même mécanisme, mais dans la limite de +3%. Par ailleurs le code général des impôts a été modifié, à l'occasion de la LFR du 30 juillet 2020 afin de diviser par quatre les quantités de produits du tabac pouvant être introduites en France depuis un autre État membre. La France est le seul pays européen à avoir pris une telle mesure au niveau UE, et elle risque une procédure de la part de la Commission européenne car cette décision va l'encontre de la Directive de 2008 fixant les seuils des produits pouvant être importés en suspension d'accise.
C215		Have you utilized the “Guidelines for implementation of Article 6 of the WHO FCTC” when developing or implementing policies in this area? Yes
C216		If you answered “Yes” to question C215 please provide details in the space below or refer to section H of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C217		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below. Les augmentations successives ces dernières années des accises sur les produits du tabac ont démontré leur efficacité pour lutter contre le tabagisme : les volumes de tabac mis à la consommation en France ont diminué de 22% entre 2017 et 2021, sous l'effet notamment de la trajectoire de hausse soutenue de la fiscalité. Un ralentissement de cette réduction de la prévalence a été remarqué concomitamment à la fin de la trajectoire d'augmentation des prix du tabac. Par ailleurs, en ce qui concerne l'évolution de la réglementation en matière fiscale, la

		Commission européenne avait prévu de présenter une initiative visant à modifier la directive 2011/64/UE relative à la structure et aux taux d'accises applicables aux produits du tabac. Cette directive, ci-après « directive tabac », prévoit notamment les taux minima que doivent pratiquer les États membres en matière d'accises sur le tabac. Dans le cadre de la révision de cette directive, la Commission devait proposer de revoir les taux minima de taxation des produits du tabac et d'élargir le champ à de nouvelles catégories de produits (notamment le tabac à chauffer, et les cigarettes électroniques ou « vapotage »). La Commission avait prévu initialement de présenter, conjointement à sa proposition de révision de la directive tabac, une proposition de révision de l'article 32 de la directive horizontale sur les accises 2008/118/CE, ci-après « directive horizontale ». Cet article 32 prévoit les seuils de présomption d'activité commerciale pour les achats transfrontaliers d'alcool et de tabac, et fixe une limite, au-delà de laquelle l'achat n'est plus considéré comme étant destiné à la consommation individuelle.
C22		Protection from exposure to tobacco smoke Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C221		- banning, completely or partially, tobacco smoking in indoor workplaces, public transport, indoor public places and, as appropriate, other public places? Yes
1		What is the type/nature of the measure providing for the ban?
	1	national law Yes
	2	subnational law(s) No
	3	administrative and executive orders Yes
	4	voluntary agreements No
	5	other measures (please specify in C223 below) No
C223		Please provide a brief explanation of the type/nature and content of the measures providing for the ban.
C224		Do any of these measures provide for a mechanism/ infrastructure for enforcement? Yes
C225		Please provide details of this system. Il est interdit de fumer dans tous les lieux publics fermés, notamment dans les cafés et restaurants. Des espaces fumeurs peuvent être aménagés. Il est également interdit de fumer dans les transports publics, les établissements scolaires, dans les aires de jeux pour enfants et sur le lieu de travail. Le responsable des lieux (le cafetier par exemple) est passible d'une amende pouvant aller jusqu'à 750 €, s'il est dans l'un des cas suivants : - Il ne met pas la signalisation prévue rappelant le principe de l'interdiction de fumer ou de vapoter - Il met à la disposition des fumeurs un emplacement réservé non conforme aux normes techniques imposées - Il favorise volontairement, par quelque moyen que ce soit, la violation de l'interdiction de fumer Le fait de fumer dans un lieu à usage collectif en dehors de l'emplacement réservé à cet effet est puni de l'amende pouvant aller jusqu'à 450€. Le fait de fumer dans un véhicule en présence d'un mineur est puni de l'amende pouvant aller jusqu'à 750 €.
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor workplaces:

	1	government buildings Complete
	2	health-care facilities Complete
	3	educational facilities⁶ Complete
	4	universities Complete
	5	private workplaces Partial
	6	other (please specify below)
C226aa		Please provide a brief explanation of any "other" policies in the space below
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Public transport:
	1	airplanes Complete
	2	trains Complete
	3	ferries Partial
	4	ground public transport (buses, trolleybuses, trams) Complete
	5	private vehicles Complete
	6	other (please specify below) Partial
C226bb		Please provide a brief explanation of any "other" policies in the space below
1		Please specify the settings and extent/comprehensiveness of measures applied in indoor workplaces, public transport, indoor public places and, as appropriate, other public places. Indoor public places:
	1	cultural facilities Partial
	2	shopping malls Partial

	3	pubs and bars Partial
	4	nightclubs Partial
	5	restaurants Partial
	7	other (please specify below)
C226cc		Please provide a brief explanation of any "other" policies in the space below
C227		Please provide a brief summary of complete and partial measures, with specific details of the partial measures that have been implemented:
C227a		Banning tobacco smoking in indoor workplaces L'article R3512-3 code de la santé publique prévoit que L'interdiction de fumer ne s'applique pas dans les emplacements qui sont mis à la disposition des fumeurs, au sein des lieux mentionnés à l'article R. 3512-2. Ces emplacements sont déterminés par la personne ou l'organisme responsable de ces lieux, en tenant compte de leur volume, disposition, condition d'utilisation, d'aération et de ventilation et de la nécessité d'assurer la protection des non-fumeurs. La création de fumeurs est facultative. La majorité d'entreprises n'ont pas de fumeurs. Ces emplacements ne peuvent pas être aménagés au sein des établissements d'enseignement publics et privés, des centres de formation des apprentis, des établissements destinés à ou régulièrement utilisés pour l'accueil, la formation, l'hébergement ou la pratique sportive des mineurs ni les établissements de santé. La création de fumeurs au sein des locaux intérieurs de l'administration publique n'est pas non plus autorisée.
C227b		Banning tobacco smoking in public transport La création de fumeurs est facultative, les sociétés gestionnaires des transports (trains, bus, metro) ont décidé de ne pas créer de fumeurs au sein des établissements sur leur responsabilité. - Interdiction complète dans les trains, cars, bus du service urbain, etc. -Interdiction partielle sur les ferrys (possibilité de fumer sur le pont) ; -l'interdiction de fumer sur les quais de gares qui ne sont pas intégralement fermés, est décidée par le préfet de département -Possibilité de créer des fumeurs dans les aéroports.
C227c		Banning tobacco smoking in indoor public places La création de fumeurs est facultative. Très peu des lieux accueillant du public ont crée des fumeurs.
C228		Please provide a brief description of the progress made in implementing Article 8 (Protection from exposure to tobacco smoke) in the past two years or since submission of your last report.
C229		Have you utilized the "Guidelines for implementation of Article 8 of the WHO FCTC" when developing or implementing policies in this area? No
C2210		If you answered "Yes" to question C229 please provide details in the space below or refer to section B of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C2211		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C23		Regulation of the contents of tobacco products Have you adopted and implemented, where

		appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C231		testing and measuring the contents of tobacco products? Yes
C232		testing and measuring the emissions of tobacco products? Yes
C233		regulating the contents of tobacco products? Yes
C234		regulating the emissions of tobacco products? Yes
C235		<p>Please provide a brief description of the progress made in implementing Article 9 (Regulation of the contents of tobacco products) in the past two years or since submission of your last report.</p> <p>La directive sur les produits du tabac (2014/40/UE) fixe des règles relatives à la fabrication, la présentation et la vente des produits du tabac et produits connexes. La directive impose aux fabricants et importateurs de déclarer ces produits auprès des autorités compétentes des États membres avant leur commercialisation. La composition, les émissions, les données toxicologiques sur les ingrédients, des études approfondies pour certains additifs ainsi que des données de marché doivent être transmises. En France l'Anses a été désignée pour recueillir ces informations et les analyser, en identifiant et en évaluant les dangers des substances chimiques auxquelles le consommateur ou son entourage sont exposés lors de l'utilisation de ces produits. L'Anses assure d'autre part une mission d'information en rendant publiques les listes des produits commercialisés qui ont été déclarés ainsi que les informations non confidentielles contenues dans les dossiers, notamment des données relatives à la composition des produits. L'ANSES produit annuellement des reports concernant les ingrédients, la composition et la conformité de produits sur le marché. Tous ces rapports sont disponibles sur le site de l'ANSES : https://www.anses.fr/fr/content/les-produits-du-tabac-et-produits-connexes</p>
C236		<p>Have you utilized the “Guidelines for implementation of Articles 9 and 10 of the WHO FCTC” when developing or implementing policies in this area?</p> <p>No</p>
C237		<p>If you answered “Yes” to question C236 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</p> <p>https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C238		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g., whether your country 1) has incorporated product regulation in the national tobacco control legislation; 2) has access to either governmental or independent – not owned or controlled by the tobacco industry – laboratories for testing contents and/or emissions of tobacco products; 3) has regulated ingredients, such as flavours (e.g. menthol); 4) has regulated product characteristics, such as design features (e.g., cigarette ventilation); etc.).</p> <p>Si vous avez d'autres informations pertinentes relevant de la présente section mais non couvertes par celle-ci, veuillez fournir des précisions dans l'espace ci-après (par ex. : si votre pays 1) a inscrit la réglementation des produits dans la législation nationale de lutte antitabac ; 2) a accès à des laboratoires du secteur public ou des laboratoires indépendants, qui n'appartiennent pas à l'industrie du tabac ou ne sont pas contrôlés par elle ; 3) a réglementé les ingrédients, comme les arômes (par ex. : le menthol) ; 4) a réglementé les caractéristiques des produits, comme les caractéristiques de la conception (par ex. : la ventilation des cigarettes) ; etc.). Pas de nouveauté réglementaire pour la période comprise dans le présent rapport.</p>
C24		Regulation of tobacco product disclosures Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:

1		requiring manufacturers or importers of tobacco products to disclose to Government authorities information about the:
	1	contents of tobacco products? Yes
	2	emissions of tobacco products? Yes
1		requiring public disclosure of information about the:
	1	contents of tobacco products? Yes
	2	emissions of tobacco products? Yes
C243		<p>Please provide a brief description of the progress made in implementing Article 10 (Regulation of tobacco product disclosures) in the past two years or since submission of your last report.</p> <p>La directive sur les produits du tabac (2014/40/UE) fixe des règles relatives à la fabrication, la présentation et la vente des produits du tabac et produits connexes. La directive impose aux fabricants et importateurs de déclarer ces produits auprès des autorités compétentes des États membres avant leur commercialisation. La composition, les émissions, les données toxicologiques sur les ingrédients, des études approfondies pour certains additifs ainsi que des données de marché doivent être transmises. En France l'Anses a été désignée pour recueillir ces informations et les analyser, en identifiant et en évaluant les dangers des substances chimiques auxquelles le consommateur ou son entourage sont exposés lors de l'utilisation de ces produits. L'Anses assure d'autre part une mission d'information en rendant publiques les listes des produits commercialisés qui ont été déclarés ainsi que les informations non confidentielles contenues dans les dossiers, notamment des données relatives à la composition des produits. L'ANSES produit annuellement des reports concernant les ingrédients, la composition et la conformité de produits sur le marché. Tous ces rapports sont disponibles sur le site de l'ANSES : https://www.anses.fr/fr/content/les-produits-du-tabac-et-produits-connexes</p>
C244		<p>Have you utilized the “Guidelines for implementation of Articles 9 and 10 of the WHO FCTC” when developing or implementing policies in this area?</p> <p>No</p>
C245		<p>If you answered “Yes” to question C244 please provide details in the space below or refer to section C of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C246		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether your country has incorporated tobacco product disclosures in the national tobacco control legislation; has regulated the public disclosure of toxic constituents and emissions of tobacco products, aiming to raise public awareness and advance tobacco control policy; etc.).</p> <p>Pas de nouveauté réglementaire pour la période comprise dans le présent rapport.</p>
C25		<p>Packaging and labelling of tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</p>
C251		<p>requiring that packaging, individual cigarettes or other tobacco products do not carry advertising or promotion?</p> <p>Yes</p>

C252		<p>requiring that packaging and labelling do not promote a product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions?</p> <p>Yes</p>
C253		<p>requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products carry health warnings describing the harmful effects of tobacco use?</p> <p>Yes</p>
C254		<p>ensuring that the health warnings are approved by the competent national authority?</p> <p>Yes</p>
C255		<p>ensuring that the health warnings are rotated?</p> <p>Yes</p>
C256		<p>ensuring that the health warnings are clear, visible and legible?</p> <p>Yes</p>
C257		<p>Does your law mandate, as a minimum, a style, size and colour of font to render the warning clear, visible and legible?</p> <p>Yes</p>
C258		<p>ensuring that the health warnings occupy no less than 30% of the principal display areas?</p> <p>Yes</p>
C259		<p>ensuring that the health warnings occupy 50% or more of the principal display areas?</p> <p>Yes</p>
C2510		<p>ensuring that health warnings are in the form of, or include, pictures or pictograms?</p> <p>Yes</p>
C2511		<p>Does the Government own the copyright to these pictures and pictograms?</p> <p>No</p>
C2512		<p>Would you grant a non-exclusive and royalty-free licence for the use of health warnings developed in your jurisdiction with other Parties?</p> <p>No</p>
1		<p>requiring that each unit packet and package of tobacco products and any outside packaging and labelling of such products contain information on relevant:</p>
	1	<p>constituents of tobacco products?</p> <p>No</p>
	2	<p>emissions of tobacco products?</p> <p>No</p>
C2514		<p>requiring that the warnings and other textual information appear on each unit packet and package and on any outside packaging and labelling in the principal language or languages of the country?</p> <p>Yes</p>
C2515		<p>Please provide a brief description of the progress made in implementing Article 11 (Packaging and labelling of tobacco products) in the past two years or since submission of your last report.</p>

C2516		<p>Have you utilized the “Guidelines for implementation of Article 11 of the WHO FCTC” when developing or implementing policies in this area?</p> <p>No</p>
C2517		<p>If you answered “Yes” to question C2516 please provide details in the space below or refer to section D of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C2518		<p>If you have any other relevant information pertaining to or not covered in this section, please provide details in the space below.</p> <p>Depuis 2017, les paquets de cigarettes et de tabac à rouler sont neutres et uniformisés. Par ailleurs, l'article L3512-21 a précisé que « L'étiquetage des unités de conditionnement, tout emballage extérieur ainsi que le produit du tabac proprement dit ne peuvent comprendre aucun élément ou dispositif qui : 1° Contribue à la promotion d'un produit du tabac ou incite à sa consommation en donnant une impression erronée quant aux caractéristiques, effets sur la santé, risques ou émissions de ce produit ou ressemble à un produit alimentaire ou cosmétique. La taille des avertissements sanitaires des paquets de cigarettes et de tabac à rouler couvre, depuis le 20 mai 2016, 65% du recto et du verso des paquets (Arrêté du 24 février 2015 modifiant l'arrêté du 15 avril 2010 relatif aux modalités d'inscription des avertissements de caractère sanitaire sur les unités de conditionnement des produits du tabac et insérant un pictogramme destiné aux femmes enceintes</p>
C26		<p>Education, communication, training and public awareness Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</p>
C261		<p>educational and public awareness programmes? (Please refer to programmes implemented since submission of your two-year report.)</p> <p>Yes</p>
1		<p>To whom are these programmes targeted?</p>
	1	<p>adults or the general public</p> <p>Yes</p>
	2	<p>children and young people</p> <p>Yes</p>
	3	<p>men</p> <p>Yes</p>
	4	<p>women</p> <p>Yes</p>
	5	<p>pregnant women</p> <p>Yes</p>
	6	<p>ethnic groups</p> <p>No</p>
	7	<p>other</p> <p>Yes</p>
C2621		<p>Please specify</p> <p>populations socioéconomiquement défavorisées</p>
1		<p>Do you reflect the following key differences among targeted population groups in</p>

		educational and public awareness programmes?
	1	age Yes
	2	gender Yes
	3	educational background Yes
	4	cultural background Yes
	5	socioeconomic status Yes
	6	other No
C2631		Please specify
1		Do these educational and public awareness programmes cover:
	1	health risks of tobacco consumption? Yes
	2	health risks of exposure to tobacco smoke? No
	3	benefits of the cessation of tobacco use and tobacco-free lifestyles? Yes
	4	adverse economic consequences of tobacco production? No
	5	adverse economic consequences of tobacco consumption? Yes
	6	adverse environmental consequences of tobacco production? No
	7	adverse environmental consequences of tobacco consumption? No
1		awareness and participation of the following agencies and organizations in development and implementation of intersectoral programmes and strategies for tobacco control:
	1	public agencies? Yes
	2	nongovernmental organizations not affiliated with the tobacco industry? Yes

	3	private organizations? Yes
	4	other No
C2651		Please specify
C266		Are the elaboration, management and implementation of communication, education, training and public awareness programmes guided by research and do they undergo pre-testing, monitoring and evaluation? Yes
1		Are appropriate and special training or sensitization and awareness programmes on tobacco control addressed to:
	1	health workers? Yes
	2	community workers? No
	3	social workers? No
	4	media professionals? No
	5	educators? No
	6	decision-makers? Yes
	7	administrators? No
	8	other No
C2671		Please specify
C268		Please provide a brief description of the progress made in implementing Article 12 (Education, communication, training and public awareness) in the past two years or since submission of your last report. De nombreuses campagnes de communication et dispositifs de marketing social ont été mis en œuvre. Notamment Mois sans tabac, renouvelé chaque année depuis 2016. Depuis 2021, la campagne de communication cible essentiellement les populations socioéconomiquement défavorisés. Des campagnes spécifiques pour ces mêmes populations ont été mises en place (par Santé publique France en février 2022 et février 2023) et en 2023 par l'ACT. L'amplification du mouvement de dénormalisation se poursuit, avec la conduite en juin 2021, mai 2022 et mai 2023 d'une campagne de dénormalisation par Santé publique France. L'Alliance contre le tabac, organisation de la société civile financée depuis 2019 dans le cadre de l'Appel à projets Mobilisation de la société civile du Fonds de prévention des addictions, a également intensifié son action de sensibilisation à travers différentes campagnes : https://alliancecontreletabac.org/nos-campagnes/ touchant différents segments de la population.

C269		<p>Have you utilized the “Guidelines for implementation of Article 12 of the WHO FCTC” when developing and implementing policies in this area?</p> <p>No</p>
C2610		<p>If you answered “Yes” to question C269 please provide details in the space below or refer to section E of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</p> <p>https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C2611		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</p>
C27		<p>Tobacco advertising, promotion and sponsorship Have you adopted and implemented, where appropriate, any legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes:</p>
C271		<p>instituting a comprehensive ban on all tobacco advertising, promotion and sponsorship?</p> <p>Yes</p>
1		<p>Does your ban cover:</p>
	1	<p>display and visibility of tobacco products at points of sales?</p> <p>Yes</p>
	2	<p>the domestic Internet?</p> <p>Yes</p>
	3	<p>the global Internet?</p> <p>No</p>
	4	<p>brand stretching and/or brand sharing?</p> <p>No</p>
	5	<p>product placement as a means of advertising or promotion?</p> <p>Yes</p>
	6	<p>the depiction of tobacco or tobacco use in entertainment media products?</p> <p>No</p>
	7	<p>tobacco sponsorship of international events or activities and/or participants therein?</p> <p>Yes</p>
	8	<p>contributions from tobacco companies to any other entity for “socially responsible causes” and/or any other activities implemented under the umbrella of “corporate social responsibility” by the tobacco industry?</p> <p>Yes</p>
	9	<p>cross-border advertising, promotion and sponsorship originating from your territory?</p> <p>No</p>
	10	<p>the same forms of cross-border advertising, promotion and sponsorship entering your territory for which domestic regulation apply?</p> <p>Yes</p>
C273		<p>are you precluded by your constitution or constitutional principles from undertaking a</p>

		comprehensive ban on tobacco advertising, promotion and sponsorship? N/A
C274		applying restrictions on all tobacco advertising, promotion and sponsorship? N/A
C275		applying restrictions on cross-border advertising, promotion and sponsorship originating from your territory with cross-border effects? N/A
C276		prohibiting those forms of tobacco advertising, promotion and sponsorship that promote a tobacco product by any means that are false, misleading, deceptive or likely to create an erroneous impression about its characteristics, health effects, hazards or emissions? N/A
C277		requiring that health or other appropriate warnings or messages accompany all tobacco advertising, promotion and sponsorship? N/A
C278		restricting the use of direct or indirect incentives that encourage the purchase of tobacco products by the public? N/A
C279		requiring the disclosure to relevant Government authorities of expenditures by the tobacco industry on advertising, promotion and sponsorship not yet prohibited? N/A
1		restricting tobacco advertising, promotion and sponsorship on:
	1	radio? N/A
	2	television? N/A
	3	print media? N/A
	4	the domestic Internet? N/A
	5	the global Internet? N/A
	6	other media? N/A
C27101		Please specify
1		restricting tobacco sponsorship of:
	1	international events and activities? N/A
	2	participants therein?

		N/A
C2712		<p>cooperating with other Parties in the development of technologies and other means necessary to facilitate the elimination of cross-border advertising?</p> <p>No</p>
C2713		<p>imposing penalties for cross-border advertising equal to those applicable to domestic advertising, promotion and sponsorship originating from your territory in accordance with national law?</p> <p>Yes</p>
C2714		<p>Please provide a brief description of the progress made in implementing Article 13 (Tobacco advertising, promotion and sponsorship) in the past two years or since submission of your last report.</p> <p>Pas d'évolution en matière de publicité et promotion</p>
C2715		<p>Have you utilized the "Guidelines for implementation of Article 13 of the WHO FCTC" when developing and implementing policies in this area?</p> <p>No</p>
C2716		<p>If you answered "Yes" to question C2715 please provide details in the space below or refer to section F of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C2717		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.</p>
C28		<p>Demand reduction measures concerning tobacco dependence and cessation Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:</p>
C281		<p>developing and disseminating appropriate, comprehensive and integrated guidelines based on scientific evidence and best practices?</p> <p>Yes</p>
1		<p>programmes to promote cessation of tobacco use, including:</p>
	1	<p>media campaigns emphasizing the importance of quitting?</p> <p>Yes</p>
	2	<p>programmes specially designed for underage girls and young women?</p> <p>No</p>
	3	<p>programmes specially designed for women?</p> <p>No</p>
	4	<p>programmes specially designed for pregnant women?</p> <p>Yes</p>
	5	<p>telephone quitlines?</p> <p>Yes</p>
	6	<p>local events, such as activities related to World No Tobacco Day or National No Smoking Day, if appropriate?</p>

		Yes
	7	other? No
C2821		Please specify
1		design and implementation of programmes aimed at promoting the cessation of tobacco use, in such locations as:
	1	educational institutions? No
	2	health-care facilities? Yes
	3	workplaces? Yes
	4	sporting environments? No
	5	other? No
C2831		Please specify
1		inclusion of diagnosis and treatment of tobacco dependence and counselling services for cessation of tobacco use in national programmes, plans and strategies for:
	1	tobacco control? Yes
	2	health? Yes
	3	education? No
C285		inclusion of programmes on the diagnosis and treatment of tobacco dependence in your health-care system? Yes
1		Which structures in your health-care system provide programmes for the diagnosis and treatment of tobacco dependence?
	1	primary health care Yes
	2	secondary and tertiary health care Yes
	3	specialist health-care systems (please specify below)

		Yes
	4	specialized centres for cessation counselling and treatment of tobacco dependence Yes
	5	rehabilitation centres No
1		Are the services provided in these settings covered by public funding or reimbursement schemes?
	1	primary health care Partially
	2	secondary and tertiary health care Partially
	3	specialist health-care systems (please specify below) Partially
	4	specialized centres for cessation counselling and treatment of tobacco dependence Partially
	5	rehabilitation centres None
	6	other (please specify below) Partially
C287b		Please provide other details in the space below. Centres de soins, d'accompagnement et de prévention en addictologie (CSAPA)
1		Which health and other professionals are involved in programmes offering treatment for tobacco dependence and counselling services? Health professionals including:
	1	physicians Yes
	2	dentists Yes
	3	family doctors Yes
	4	practitioners of traditional medicine No
	5	other medical professionals (please specify below) Yes
	6	nurses Yes
	7	midwives Yes

	8	pharmacists No
	9	Community workers No
	10	Social workers No
	11	other (please specify) Yes
1		training on tobacco dependence treatment incorporated into the curricula of health professional training at pre- and post-qualification levels at the following schools:
	1	medical? Yes
	2	dental? No
	3	nursing? Yes
	4	pharmacy? No
C2810		facilitating accessibility and/or affordability of pharmaceutical products for the treatment of tobacco dependence? Yes
C2811		Where and how can these products be legally purchased in your country? En pharmacie. En cas de prescription (médecin, dentiste, infirmier, sage-femme, masseur-kinésithérapeute l'assurance Maladie prend en charge à hauteur 65% les traitements par substituts nicotiniques (patch, gomme, pastille, inhalateur...)
1		Which pharmaceutical products are legally available for the treatment of tobacco dependence in your jurisdiction?
	1	nicotine replacement therapy Yes
	2	bupropion Yes
	3	varenicline Yes
	4	other (please specify) No
1		Are the costs of these products covered by public funding or reimbursement?
	1	nicotine replacement therapy Partially

	2	bupropion None
	3	varenicline Partially
	4	other (please specify below) None
C2813b		Please provide other details in the space below.
C2814		<p>Please provide a brief description of the progress made in implementing Article 14 (Demand reduction measures concerning tobacco dependence and cessation) in the past two years or since submission of your last report.</p> <p>En 2021, les ventes de traitements d'aide à l'arrêt du tabac (traitements nicotiniques de substitution/TNS) réalisées en pharmacie enregistrent une augmentation de 14,4 % (7 030 284 ventes en équivalents mois de traitement⁵). Elle est concomitante avec la tendance à la hausse des tentatives d'arrêt d'au moins une semaine de ces dernières années. Elles concernent 30 % des fumeurs quotidiens en 2020, proportion en baisse par rapport à 2019 (33 %), mais qui reste supérieure aux années précédentes (autour de 25 % entre 2016 et 2018) (Pasquereau et al., 2021). Cette hausse est favorisée par l'ensemble des politiques publiques qui incitent à la sortie du tabagisme, parmi lesquelles la disparition du forfait TNS au 1er janvier 2019 permettant désormais un remboursement de ces produits selon un régime de droit commun et une meilleure accessibilité financière, comme en atteste l'augmentation de la part des bénéficiaires de la complémentaire santé solidaire (ex-CMUc). Plus de 75 spécialités sont concernées à ce jour : dispositifs transdermiques, gommes à mâcher, comprimés et pastilles... Cette extension s'est aussi accompagnée d'un élargissement et d'une diversification des prescripteurs puisque, depuis le 1er janvier 2016, les infirmiers, les masseurs-kinésithérapeutes, les sages-femmes, les chirurgiens-dentistes et les médecins du travail peuvent prescrire des substituts nicotiniques. Le nombre de prescripteurs de ces traitements a donc connu une forte augmentation puisqu'ils sont près de 112 273 en 2020 (soit une augmentation de plus de 50 000 depuis 2017). Les médecins généralistes représentent 71 % des principaux prescripteurs, suivis des cardiologues, psychiatres, gynécologues et pneumologues. (Source Bilan Tableau de bord Tabac OFDT 2021 : https://www.ofdt.fr/ofdt/fr/tt_21bil.pdf)</p>
C2815		<p>Have you utilized the “Guidelines for implementation of Article 14 of the WHO FCTC” when developing and implementing policies in this area?</p> <p>No</p>
C2816		<p>Please provide details in the space below or refer to section G of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C2817		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

C3. MESURES RELATIVES À LA RÉDUCTION DE L'OFFRE DE TABAC

C3		With reference to Articles 15–17
C31		Illicit trade in tobacco products Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C311		requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining the origin of the product? Yes
C312		requiring marking of all unit packets and packages of tobacco products and any outside packaging of such products to assist in determining whether the product is legally sold on the domestic market? Yes
C313		requiring that unit packets and packages of tobacco products for retail and wholesale use that are sold on the domestic market carry the statement: “Sales only allowed in ...” or carry any other effective marking indicating the final destination of the product? Yes
C314		developing a practical tracking and tracing regime that would further secure the distribution system and assist in the investigation of illicit trade? Yes
C315		requiring that marking is presented in legible form and/or appears in the principal language or languages of the country? Yes
C316		requiring the monitoring and collection of data on cross-border trade in tobacco products, including illicit trade? Yes
C317		facilitating the exchange of this information among customs, tax and other authorities, as appropriate, and in accordance with national law and applicable bilateral and multilateral agreements? Yes
C318		enacting or strengthening legislation, with appropriate penalties and remedies, against illicit trade in tobacco products, including counterfeit and contraband cigarettes? Yes
C319		requiring that confiscated manufacturing equipment, counterfeit and contraband cigarettes and other tobacco products derived from illicit trade are destroyed, using environment-friendly methods where possible, or disposed of in accordance with national law? Yes
C3110		adopting and implementing measures to monitor, document and control the storage and distribution of tobacco products held or moving under suspension of taxes or duties? Yes
C3111		enabling the confiscation of proceeds derived from illicit trade in tobacco products? Yes
C3112		promoting cooperation between national agencies and relevant regional and international intergovernmental organizations in investigations, prosecutions and proceedings, with a view to eliminating illicit trade in tobacco products, with special emphasis on cooperation at regional and subregional levels?

		Yes
C3113		licensing or other actions to control or regulate production and distribution in order to prevent illicit trade? Yes
C3114		Please provide a brief description of the progress made in implementing Article 15 (Illicit trade in tobacco products) in the past two years or since submission of your last report. Depuis 2019 les paquets commercialisées en France disposent d'un marquage unique, sécurisé, apposé de façon inamovible et indélébile sur chaque conditionnement permettant d'identifier l'origine et la destination de chaque produit du tabac
C3115		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C32		Sales to and by minors Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
C321		prohibiting the sales of tobacco products to minors? Yes
C321a		Please specify the legal age: 18
C322		requiring that all sellers of tobacco products place a clear and prominent indicator inside their point of sale about the prohibition of tobacco sales to minors? Yes
C323		requiring that, in case of doubt, each seller of tobacco products requests that the purchaser provides appropriate evidence of having reached full legal age? Yes
C324		banning the sale of tobacco products in any manner by which they are directly accessible, such as open store shelves? Yes
C325		prohibiting the manufacture and sale of sweets, snacks, toys or any other objects in the form of tobacco products which appeal to minors? No
C326		prohibiting the sale of tobacco products from vending machines? Yes
C327		Do you ensure that tobacco vending machines are not accessible to minors and/or do not promote the sale of tobacco products to minors? N/A
1		prohibiting and/or promoting the prohibition of the distribution of free tobacco products:
	1	to the public? Yes
	2	to minors? Yes

C329		prohibiting the sale of cigarettes individually or in small packets? Yes
C3210		providing for penalties against sellers and distributors in order to ensure compliance? Yes
C3211		prohibiting the sales of tobacco products by minors? Yes
C3212		Please provide a brief description of the progress made in implementing Article 16 (Sales to and by minors) in the past two years or since submission of your last report. Une étude réalisé en 2021 montre que 64% des buralistes ont continué de vendre du tabac à des mineurs de 17 ans, contre 65,1% lors de la précédente enquête menée en 2019. Le constat est d'autant plus inquiétant dans les villes de plus de 15 000 habitants, où 77% des buralistes acceptent de vendre du tabac à des mineurs. En prenant en compte les conditions cumulatives, à savoir l'existence d'une affichette, conforme à l'arrêté et visible, lisible au client qui entre dans le débit, en 2021, seuls 42% des débitants respectaient l'ensemble de ces obligations. Ils étaient 49% à la précédente enquête, correspondant à une certaine dégradation.
C3213		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C33		Provision of support for economically viable alternative activities Have you adopted and implemented, where appropriate, measures or programmes on any of the following:
1		promoting economically viable and sustainable alternatives for:
	1	tobacco growers? No
	2	tobacco workers? No
	3	tobacco individual sellers? Yes
C332		Please provide a brief description of the progress made in implementing Article 17 (Provision of support for economically viable alternative activities) in the past two years or since submission of your last report. Création d'un Fonds de Transformation, doté de 20 millions d'euros par an, jusqu'en 2021 pour donner à la profession les moyens de mener ses projets et contribuer au développement commercial des points de vente : passer du modèle de débitant de tabac à celui de nouveau commerçant de proximité
C333		Have you utilized the “Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)” when developing and implementing policies in this area? No
C334		Please provide details in the space below or refer to section I of the additional questionnaire. Response to this question or to the additional questionnaire is voluntary. https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en
C335		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.

C4. OTRAS MEDIDAS Y POLÍTICAS

C4		With reference to Articles 18–21
C41		Protection of the environment and the health of persons Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
1		implementing measures in respect of tobacco cultivation within your territory, which take into consideration:
	1	the protection of the environment? Yes
	2	the health of persons in relation to the environment? No
1		implementing measures in respect of tobacco manufacturing within your territory, which take into consideration:
	1	the protection of the environment? No
	2	the health of persons in relation to the environment? No
C413		<p>Please provide a brief description of the progress made in implementing Article 18 (Protection of the environment and the health of persons) in the past two years or since submission of your last report.</p> <p>Le ministère de la transition Ecologique a réalisé la transposition de la Directive européenne sur la réduction de plastiques à usage unique. Elle prévoit que les fabricants de tabac sont soumis au régime de la REP (responsabilité élargie du producteur) , car les mégots de cigarette contiennent du plastic. Ce régime impose aux producteurs d'assurer ou de financer la collecte, le traitement et recyclage des déchets qu'ils produisent.</p>
C414		<p>Have you utilized the “Policy options and recommendations on economically sustainable alternatives to tobacco growing (in relation to Articles 17 and 18 of the WHO FCTC)” when developing and implementing policies in this area?</p> <p>No</p>
C415		<p>If you answered “Yes” to question C414 please provide details in the space below or refer to section I of the additional questionnaire available at this link. Response to this question or to the additional questionnaire is voluntary.</p> <p>https://extranet.who.int/dataformv3/862235?token={TOKEN}&lang=en</p>
C416		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C42		Liability Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:
SQ001		Does your tobacco control legislation contain measures regarding criminal liability for any violations of that tobacco control legislation?

	SQ001	Yes
SQ001		Do you have separate criminal liability provisions in relation to tobacco control (outside of the tobacco control legislation)?
	SQ001	Yes
SQ001		Do you have any civil liability measures that are specific to tobacco control?
	SQ001	No
SQ001		Do you have any general civil liability provisions that could apply to tobacco control?
	SQ001	Yes
SQ001		Do you have civil or criminal liability provisions that provide for compensation for adverse health effects and/or for reimbursement of medical, social or other relevant costs?
	SQ001	No
SQ001		?Has any person in your jurisdiction launched any criminal and/or civil liability action, including compensation where appropriate, against any tobacco company in relation to any adverse health effect caused by tobacco use?
	SQ001	Yes
SQ001		Have you taken, as appropriate, any legislative, executive, administrative and/or other action against the tobacco industry for full or partial reimbursement of medical, social and other relevant costs related to tobacco use in your jurisdiction?
	SQ001	No
C428		Please provide a brief description of any progress made, as appropriate, in implementing Article 19 (Liability) in the past two years or since submission of your last report. Pas de nouvelles dispositions dans la période concernée par ce rapport.
C429		If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below.
C43		Research, surveillance and exchange of information Have you adopted and implemented, where appropriate, legislative, executive, administrative or other measures or have you implemented, where appropriate, programmes on any of the following:

1		developing and/or promoting research that addresses:
	1	determinants of tobacco consumption? Yes
	2	consequences of tobacco consumption? Yes
	3	social and economic indicators related to tobacco consumption? Yes
	4	tobacco use among women, with special regard to pregnant women? Yes
	5	the determinants and consequences of exposure to tobacco smoke? Yes
	6	identification of effective programmes for the treatment of tobacco dependence? Yes
	7	identification of alternative livelihoods? No
C4311		Please specify
C432		training and support for all persons engaged in tobacco control activities, including research, implementation and evaluation? Yes
1		a national system for epidemiological surveillance of:
	1	patterns of tobacco consumption? Yes
	2	determinants of tobacco consumption? Yes
	3	consequences of tobacco consumption? Yes
	4	social, economic and health indicators related to tobacco consumption? Yes
	5	exposure to tobacco smoke? Yes
C4331		Please specify
C434		Please list all surveys, including the year of the survey, that you have undertaken in the past. Baromètre santé (population générale) : 2005, 2010, 2015, 2016, 2017,2018 , 2020, 2021,2022 Escapad (17 ans) : 2005, 2008, 2011, 2014, 2017, 2019,2018,2022 Enquête EnCLASS 2018

		Enquête ARAMIS 2017 Enquête ATLAS 2017 Enquête ESPAD 2015 Enquête Health Behaviour in School-aged Children (HBSC) 2014 International tobacco control (ITC) : 2006, 2008, 2011
C435		<p>Does your country have any plans to repeat any of the above or to undertake a new tobacco survey within three to five years of your last survey? Please provide details in the space below.</p> <p>Barometre santé: tous les deux ans Escapad : tous les 2 ans</p>
1		regional and global exchange of publicly available national:
	1	<p>scientific, technical, socioeconomic, commercial and legal information?</p> <p>Yes</p>
	2	<p>information on the practices of the tobacco industry?</p> <p>Yes</p>
	3	<p>information on the cultivation of tobacco?</p> <p>No</p>
1		an updated database of:
	1	<p>laws and regulations on tobacco control?</p> <p>Yes</p>
	2	<p>information about the enforcement of laws on tobacco control?</p> <p>No</p>
	3	<p>pertinent jurisprudence?</p> <p>No</p>
C438		<p>Please provide a brief description of the progress made in implementing Article 20 (Research, surveillance and exchange of information) in the past two years or since submission of your last report.</p> <p>Les travaux des instances de gestion du fonds de prevention des addictions ont permis de dégager des orientations prioritaires, dont celle de soutenir financièrement la recherche par des appels annuels gérés par un pôle constitué par l'Institut national du Cancer (INCa) et l'IREPS</p>
C439		<p>If you have any other relevant information pertaining to but not covered in this section, please provide details in the space below (e.g. whether you included information on WHO FCTC implementation in your Voluntary National Review (VNR) on the Sustainable Development Goals (SDGs), related to target 3.a).</p>

D. COOPÉRATION ET AIDE INTERNATIONALES

D0		Pursuant to Article 21.1(c) and in accordance with Article 26, have you either provided or received financial or technical assistance (be it through unilateral, bilateral, regional, subregional or other multilateral channels, including relevant regional and international intergovernmental or nongovernmental organizations and financial and development institutions) for the development and strengthening of multisectoral, comprehensive tobacco control programmes of developing country Parties and Parties with economies in transition in any of the following areas:
1		development, transfer and acquisition of technology, knowledge, skills, capacity and expertise related to tobacco control?
	1	Assistance provided Yes
	2	Assistance received Yes
1		provision of technical, scientific, legal and other expertise to establish and strengthen national tobacco control strategies, plans and programmes?
	1	Assistance provided Yes
	2	Assistance received No
1		appropriate training or sensitization programmes for appropriate personnel in accordance with Article 12?
	1	Assistance provided No
	2	Assistance received No
1		provision of the necessary material, equipment and supplies, as well as logistic support, for tobacco control strategies, plans and programmes?
	1	Assistance provided No
	2	Assistance received No
1		identification of methods for tobacco control, including comprehensive treatment of nicotine addiction?
	1	Assistance provided No
	2	Assistance received

		No
1		promotion of research to increase the affordability of comprehensive treatment of nicotine addiction?
	1	Assistance provided No
	2	Assistance received No
D7		<p>Please identify the Party or Parties from which assistance was received or to which assistance was provided.</p> <p>Le 5 juillet 2022, le secrétariat de la CCLAT signé un mémorandum de collaboration pour une durée de 6 ans, avec l'Agence nationale de Santé publique, Sante publique France, visant à la création du premier WHO FCTC Knowledge Hub sur l'éducation, la communication, la formation et la sensibilisation du public, domaines visés à l'article 12 de la Convention-cadre de l'OMS. Cette plateforme Knowledge Hub est le premier avec un contenu bilingue français-anglais. Par ailleurs, la France participe au Groupe de travail Experts Tabac de la Commission Européenne, au sein duquel sont échangés avec les autres Etats membres les avancements et difficultés dans l'application des dispositions de lutte antitabac. Elle participe également à L'action Conjointe (Joint –action) sur les produits du Tabac de Commission Européenne (JACT 2), ainsi qu'au Global Tobacco Regulators Forum.</p>
D8		Please provide information about any assistance provided or received in the space below, including any support received from nongovernmental organizations (please, specify).
D9		If you have not received or provided assistance in any of the aforementioned areas, please identify any financial or technical assistance that may be under consideration, if appropriate.
D10		<p>Have you encouraged relevant regional and international intergovernmental organizations and financial and development institutions in which you are represented to provide financial assistance for developing country Parties and for Parties with economies in transition to assist them in meeting their obligations under the Convention?</p> <p>No</p>
D11		Please provide details in the space below.

E. PRIORITÉS ET OBSERVATIONS

E1		<p>What are the priorities for implementation of the WHO Framework Convention on Tobacco Control in your jurisdiction?</p> <p>Réduction de la demande (mesures fiscales) ; réglementation de la composition du tabac et surveillance des nouveaux produits du tabac à chauffer ; sensibilisations du public, renouvellement de l'action moi(s) sans tabac et des campagnes grand public; aide au sevrage tabagique (remboursement des TNS, élargissement de l'offre d'accompagnement) ; élargissement du nombre des lieux sans tabac, renforcement du respect des interdits protecteurs, financement des actions de recherche via le fonds tabac.</p>
E2		<p>Have you identified any specific gaps between the resources available and the needs assessed for implementing the WHO Framework Convention on Tobacco Control?</p> <p>Yes</p>
E3		<p>Please provide details in the space below.</p>
E4		<p>What, if any, are the constraints or barriers, other than lack of resources, you have encountered in implementing the Convention?</p>
1		<p>Do you have any of the following products available on your national tobacco market?</p>
	1	<p>smokeless tobacco products</p> <p>Yes</p>
	2	<p>water pipe tobacco</p> <p>Yes</p>
	3	<p>Electronic Nicotine Delivery Systems (ENDS)</p> <p>Yes</p>
	4	<p>Electronic Non-Nicotine Delivery Systems (ENNDS)</p> <p>Yes</p>
	5	<p>heated tobacco products (HTPs)</p> <p>Yes</p>
1		<p>Have you adopted and implemented any policy or regulation that is specific to the following tobacco products?</p>
	1	<p>smokeless tobacco products</p> <p>Yes</p>
	2	<p>water pipe tobacco</p> <p>Yes</p>
	3	<p>Electronic Nicotine Delivery Systems (ENDS)</p> <p>Yes</p>
	4	<p>Electronic Non-Nicotine Delivery Systems (ENNDS)</p> <p>Yes</p>
	5	<p>heated tobacco products (HTPs)</p> <p>Yes</p>

E7		<p>If you have any relevant information related to questions E5 and E6, please provide details in the space below.</p> <p>Les produits du tabac sans fumée et le tabac pour pipe à eau sont considérés comme des produits du tabac : toutes les dispositions du code de la santé (interdiction de vente aux mineurs, interdiction de la publicité, interdiction de fumer dans les lieux Publics) leur sont applicables. Ces produits ne sont pas soumis au paquet neutre, et ont une fiscalité inférieure à celle de cigarettes et tabac à rouler. Les produits du vapotage sont soumis aux dispositions issues de la Directive 2014/40/UE ; interdiction de vente aux mineurs, interdiction de vapoteurs sur certains lieux à usage collectif, obligation de notification d'ingrédients, interdiction de la publicité.</p>
E8		<p>Do you have a costed national tobacco control plan or strategy?</p> <p>No</p>
E81		<p>If you answered “Yes” to question E8, is this costed national tobacco control plan or strategy fully funded?</p> <p>N/A</p>
E82		<p>Please attach the costed plan or strategy here.</p>
E9		<p>Please provide the government’s expenditure on tobacco control, for the latest year available, in your country’s currency.</p>
E10		<p>Have you adopted and implemented any national legislative, executive, administrative and/or other measures that go beyond the requirements of the Convention in line with Article 2.1 (e.g, endgame strategies, smoke-free generations, tobacco free villages or cities)?</p> <p>Yes</p>
E101		<p>If you answered “Yes” to question E10, please provide details.</p> <p>Villes sans tabac, projet pilote financé par le Fonds de prevention des addictions</p>
E11		<p>Please attach any documentation relevant to any sections of the reporting instrument.</p>
E12		<p>Please provide any other relevant information not covered elsewhere that you consider important.</p> <p>La France travail a l'élaboration d'un nouvel Programme de lutte contre le tabac 2023-2027</p>
E13		<p>Your suggestions for further development and revision of the reporting instrument:</p>